Drug, bio-affecting and body treating compositions inventions 04/06

20060088471 - Compounds for enzyme inhibition: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like and PGPH activities of the 20S proteasome can be selectively inhibited with the...

20060088472 - E7 regulation of p21 cip1 through akt: Disclosed are compositions and methods for inhibiting E7 effects on Akt, such as preventing the nuclear localization of p21Cip1....

20060088473 - Treatment screening methods: The invention includes a method to identify a method to enhance survival of a subject such as a non-human primate that has been exposed to a biological insult such as an ionizing radiation dose of about LD30/30 or about LD50/30 by treating the exposed subject with a test compound an...

20060088474 - Endohedral metallofullerene contrast agents: An image contrast agent for creating an image of a portion of a body is disclosed. The contrast agent can provide contrast for two different types of imaging techniques, such as x-ray imaging and magnetic resonance imaging. The contrast agent includes an endohedral metallofullerene compound with an atom encapsulated in...

20060088475 - Self-immolative magnetic resonance imaging contrast agents sensitive to beta-glucuronidase: The present invention relates to magnetic resonance imaging (MRI) contrast agent. In particular, the present invention provides MRI contrast agents that are sensitive to the enzyme beta-glucoronidase. The MRI contrast agents provide compositions and methods for non-invasive diagnostic imaging of tissues, including necrotic tumors....

20060088476 - Loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same: Particles are provided for use in therapeutic and/or diagnostic procedures. The particles include poly[bis(trifluoroethoxy) phosphazene] and/or a derivatives thereof which may be present throughout the particles or within an outer coating of the particles. The particles can also include a core having a hydrogel formed from an acrylic-based polymer. Barium...

20060088478 - Apparatus and method for applying cosmetic and/or therapeutic formulations: An apparatus, a method for manufacturing the apparatus, and a method for dispensing a formulation to a person or animal using the apparatus, wherein the apparatus includes: a dispensing container; an amount of formulation contained in the container; and a propellant contained in the container, wherein the propellant comprises between...

20060088477 - Compositions and methods of dispensing palliative or therapeutic agents: The present invention is a palliative or therapeutic foam for medicating or treating affected biological tissue having a pH of 7.0 to 8.0 and including a hydrated dialkali monometal complex such as disodium monocopper(II) citrate dihydrate or disodium monozinc(II) citrate dihydrate and triethanolamine lauryl sulfate in a concentration of less...

20060088479 - Particle formulation and its preparation: Powder compositions are prepared which compose microparticles having a bioactive agent dispersed therein. The compositions are prepared by spray drying a solution or suspension of the bioactive and collecting the resulting microparticles using a separator....

20060088480 - Oral composition for stabilization, (re)calcification and (re)mineralization of tooth enamel and dentine: An oral composition for the stabilization, (re)calcification and (re)mineralization of dental enamel and dentin to create an efficient protection from tooth decay is based on the use of calcium form of zeolite, phosphate salts soluble in water and matrix proteins of teeth and the adjustment of pH in the mouth...

20060088482 - Oral and dental care agent: The invention relates to oral and dental care agents, containing: an active ingredient combination (A) of at least one cationic component with an anti-bacterial action, (B) at least one active ingredient with an anti-tartar action, selected from the group of azacycloalkane diphosphonic acids or their phnysiologically compatible salts and (C)...

20060088481 - Topical oral dosage forms containing bismuth compounds: Topical oral dosage forms containing bismuth compounds are described, which are useful for treating H. pylori and other bacterial infections that cause gastrointestinal disorders and halitosis, as well as for treating ocular and dermal wounds. Methods of employing topical oral dosage forms for treating bacterial infections that cause gastrointestinal disorders...

20060088483 - Kit and method of applying makeup: The present invention relates to a kit for applying makeup to a surface such as the skin, the nails, hair, or the lips, said kit comprising: a first cosmetic composition including magnetic particles that are movable under the effect of a magnetic field; a second cosmetic composition for covering or...

20060088484 - Method of applying makeup to a surface and a kit for implementing such a method: The present invention relates to a method of applying makeup to a surface, such as the skin, the nails, hair, or the lips, said method comprising the following steps: depositing at least a first cosmetic composition in the fluid state on the surface, said composition containing magnetic particles that are...

20060088485 - Melanogenesis inhibitor and skin preparation containing the same: wherein R is a straight chain or branched chain alkyl group having 3 to 18 carbon atoms, a straight chain or branched chain alkenyl group having 3 to 18 carbon atoms, or an optionally substituted alicyclic alkyl group. The melanogenesis inhibitor is superior in stability and safety and has a...

20060088486 - Topical use of post-application expanding cosmetic composition: The present invention provides a method for imparting to the lips the appearance of more fullness and to the skin, particularly the face, the masking of surface irregularities, such as fine lines, wrinkles, and blemishes, by applying thereto a post-application expanding composition. The composition comprises one or more surfactants, a...

20060088487 - Block ethylenic copolymers comprising a vinyllactam block, cosmetic or pharmaceutical compositions containing them and cosmetic use of these copolymers: and from 1% to 48% by weight of at least one ionic hydrophilic monomer; and at least one block B obtained from monomers not comprising an ethylenic monomer comprising a lactam ring of formula (I), or comprising a minor proportion thereof; a cosmetic or pharmaceutical composition, such as a hair...

20060088488 - Dyeing composition comprising a mixture of at least one pigment and at least one electrophilic monomer: Disclosed is a dyeing keratin materials comprising applying to said materials at least one composition comprising, in a suitable dyeing medium, at least one electrophilic monomer, at least one colored pigment and at least one pigment that has a refractive index greater than the at least one colored pigment....

20060088489 - Sustained release of active molecules from polymers topically applied to skin or hair: The invention relates to a polymer for topical delivery of biologically active ingredients, the polymer comprising at least one moiety: U-B-A in which U represents a physiologically acceptable unit of an oligomer or polymer, A represents a biologically active component, and B represents one or more bond(s) linking A to...

20060088490 - Method for treating hair: The present invention provides a treating method having a good continuity of the reform effects of the hair, and which is also excellent in safety. In the method, a hair inside repair agent including at least water and a component to repair an inside of the hair is applied as...

20060088493 - Composition and process for the cosmetic treatment of keratin materials based on electrophilic monomers and non-silicone polymers: The present patent application relates to a process for the cosmetic treatment of keratin materials, including keratin fibers such as the hair. The process comprises applying the composition to the keratin materials, wherein the composition comprises, in a cosmetically acceptable medium, at least one electrophilic monomer and at least one...

20060088492 - Hair treatment agents: The invention relates to cosmetic agents for treating, particularly for caring for, human hair. These agents contain an active combination consisting of: (A) at least one water-insoluble volatile silicone; (B) at least one cationic polymer, and; (C) at least one additional hair care substance selected from the group consisting of...

20060088491 - Novel polyol-glycoside compositions for the skin: The invention concerns novel polyol-glycoside compositions for topical use. The invention is characterized in that said compositions contain an efficient amount of polyol-glycoside obtained by acetalization of a polyol of formula (I), wherein n is an integer equal to 2, 3 or 4; or of formula (II), wherein m is...

20060088494 - Method of treating hair with form memory polymers: A method for the provision of a recallable hair transformation using shape-memory polymers is disclosed. In this respect a composition which comprises a macromer or prepolymer which is cross-linkable to a shape-memory polymer is applied onto the hair and the hair is brought into a defined (permanent) shape and subsequently...

20060088496 - Personal care compositions with salts of hydroxypropyl trialkylammonium substituted mono-saccharide: A personal care composition is provided which includes a quaternary ammonium compound which is a salt of hydroxypropyl tri(C1-C3 alkyl) ammonium mono-substituted mono-saccharide. Particularly preferred are hydroxypropyl trimonium quaternized glucose or fructose. These quaternary ammonium salts provide moisturization properties to the personal care composition both in high and low relative...

20060088495 - Personal care products which include dihydroxypropyltri(c1-c3 alkyl) ammonium salts: A personal care product is provided which includes a composition containing dihydroxypropyltri(C1-C3 alkyl) ammonium salt in a carrier. The composition is packaged for delivery to a consumer and includes instructions printed on or associated with the packaging indicating topical use of the composition on skin, hair or the oral mucosae....

20060088497 - Topical skin care composition: A topical skin care product formula having a beneficial effect on the user's face and/or neck skin and appearance. The formula can be used for preparation of a skin cream and/or skin serum to be rubbed into the skin and/or a liquid to be applied to a pad and placed...

20060088498 - Anti-microbial composition using in-situ generation of an oxidizing agent: A composition for providing an antimicrobial oxidizing agent is presented. The composition includes a core containing a reactant, and a reactor wall forming a reactor space that contains the core. The reactant generates an antimicrobial oxidizer product through a chemical reaction when contacted by a main solvent. The reactor wall...

20060088499 - Amphiphilic dendritic dipeptides & their self-assembly into helical pores: An amphiphilic dendritic dipeptide, comprises a dipeptide(s) comprising one or more of a naturally occurring or synthetic amino acids and a dendron. These are suitable for use in various formulations, films, coatings, membranes and sensors, among other applications....

20060088500 - Animal lure candle: A candle is formed from a heated mixture of liquid wax, an animal attracting scent, and a scent retention additive. A wire core wick imbedded in the candle mixture is lighted to give off the animal attracting scent into the air. A container shields the candle from the wind, but...

20060088501 - Duffy antigen receptor for chemokines and use thereof: The invention relates to Duffy antigen receptor for chemokines and uses thereof. In one embodiment, the invention provides a method for screening for drug candidates that inhibit angiogenesis. The method comprises contacting a molecule with a Duffy antigen receptor for chemokines and determining whether the molecule binds to the Duffy...

20060088502 - Drug for reducing side effects in ribavirin interferon combination therapy: There is provided a drug for reducing side effects, anemia in particular, in combination therapy of chronic hepatitis C with ribavirin and interferon, which contains as the active ingredient at least one member selected from the group consisting of eicosapentaenoic acid (EPA) and pharmaceutically acceptable salts and esters thereof....

20060088503 - Cellular and genetic intervention to treat ventricular tachycardia: A method for decreasing risk of ventricular tachycardia following myocardial infarction increases cell-to-cell coupling and/or excitability in the border zone of an infarcted region of myocardial tissue. Enhanced conduction to treat the border zone is carried out by genetically modifying myocytes in the border zone to form more gap junctions...

20060088504 - Compositions and methods for effecting the levels of high density lipoprotein (hdl) cholesterol and apolipoprotein al, very low density lipoprotein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol: Compositions and methods for raising the level of HDL cholesterol and apolipoprotein AI in a patient and for lowering the levels of VLDL cholesterol and LDL cholesterol in a patient, including compositions and methods which effect the expression of a gene, LIPG, which encodes a lipase enzyme that is a...

20060088511 - Cancer therapy sensitizer: The present invention relates to compositions and methods for sensitizing cancer therapy. The invention provides such compositions comprising a SPARC family polypeptide or polynucleotide, as well as recombinant cells containing a SPARC family polypeptide or polynucleotide. The compositions and methods of the invention are useful in in vitro study of...

20060088512 - Treatment of t cell disorders: The present invention relates to a method for treating a T cell disorder in a subject involving disrupting sex steroid signaling to the thymus and introducing into the subject bone marrow or haemopoietic stem cells (HSC)....

20060088513 - Antiallergic composition: As for means for solving the object, it is to provide an antiallergic composition comprising as active ingredients the lactic acid bacteria showing equal interleukin 12 production level compared to when Lactobacillus paracasei KW 3110 strain is used as the lactic acid bacteria to be tested, or showing 60% or...

20060088514 - Formulation comprising a bacterial strain: An injectable formulation of a bacterial strain such as a Lactobacillus salivarius strain is useful in treating of inflammatory disorders such as colitis or arthritis....

20060088505 - Hair follicle mesenchymal stem cells and use thereof: The present invention relates to a method for isolating hair follicle mesenchymal stem cells and to the use thereof for therapy and prophylaxis as well as for cosmetic treatments....

20060088509 - Isolated clk-1 -/- cells from clk-1 heterozygous animals and their use in treating oxidative stress disorders: The invention relates to the field of oxidative stress disorder and more specifically to isolated cells from clk-1 +/− animals that do not express CLK1. The invention also relates to methods for treating a subject or a diseased tissue in need of treatment for oxidative stress disorder using isolated clk-1...

20060088508 - Method for obtaining characterized muscle-derived cell populations and uses: A method for obtaining cell populations derived from the muscular tissue and their use for preparing cell therapy products includes culturing cells previously removed by biopsy from skeletal muscular tissues, identifying the different types of cells present at different stages of culture, selecting the culture stage on the basis of...

20060088506 - Process for producing cartilage cells for transplantation: This invention is intended to provide a method to quickly obtain a large amount of normal human chondrocytes or a mass thereof without fear of bacterial or viral infection. Namely, a method of producing human chondrocytes characterized by comprising co-culturing chondrocytes obtained from a cartilage having perichondrium, for example, auricular...

20060088507 - Rhodamine derivatives for photodynamic diagnosis and treatment: The present invention relates to the use of the photoactivable derivatives for the photodynamic treatment for the selective destruction and/or inactivation of immunologically reactive cells without affecting the normal cells and without causing systemic toxicity for the patient, wherein appropriate intracellular levels of said derivatives are achieved and irradiation of...

20060088510 - Targeted delivery of biological factors using self-assembling peptide nanofibers: The present invention is directed to methodology that allows a variety of compounds to be attached to self-assembling peptides using biotin/streptavidin linkages. The peptides can be used to form a biologically compatible membrane that promotes the growth and differentiation of cells. The attached therapeutic agents can be used to promote...

20060088515 - Methods and devices for sustained in-vivo release of an active agent: The present invention includes methods and devices for providing sustained in-vivo release of an active agent to a subject. In some aspects, such release may be achieved by reacting an active agent in-vivo with a depot forming agent in order to form a sustained release active agent depot inside the...

20060088516 - Synthetic peptide combinations and methods of producing same: Preparation containing synthetic peptide combinations for application to humans or animals, wherein the peptide combinations originate from the partial hydrolysis of tissues from the human organism, wherein the peptide combinations are obtained from the neosynthesis of peptides, with the latter corresponding in their structure and composition to the tissue of...

20060088517 - Compounds and methods for treating seizure disorders: This invention provides methods for alleviating paroxysmal disorders in an animal, particularly epilepsy, by modulating glycolysis in brain cells....

20060088519 - Malignant tumor-inhibiting preparation comprising des a fibrin: A malignant tumor-inhibiting preparation is provided which comprises Des A fibrin and therefore can inhibit the spreading and migration of malignant tumor cells and thereby can inhibit the malignant tumors....

20060088518 - Stable thrombin composition: The stable thrombin composition comprises purified thrombin, human albumin and a neutral salt, the resulting product being stable when stored as a lyophilisate or frozen and is adjusted to a nominal strength of 500 IU of thrombin or more per ml of solution, the human albumin being in a concentration...

20060088523 - Antibody formulations: The present application describes antibody formulations, including monoclonal antibodies formulated in histidine-acetate buffer, as well as a formulation comprising an antibody that binds to domain II of HER2 (for example, Pertuzumab), and a formulation comprising an antibody that binds to DR5 (for example, Apomab)....

20060088520 - Antigen presenting cell targeting conjugate, an antigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their production or generation: The invention relates to a conjugate for targeting antigen presenting cells comprising: at least one antigenic moiety conjugated to a targeting moiety that is capable of binding to a cell surface structure of an antigen presenting cell, wherein the conjugate is capable of being internalized and processed by said antigen...

20060088521 - Composition and method for cancer treatment: Anti-CEACAM6 antibodies and antibody fragments, nucleic acids encoding them, methods of their manufacture, and methods to treat cancer using these compounds are provided....

20060088527 - Compositions and methods for the therapy and diagnosis of lung cancer: Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides....

20060088522 - Humanized anti-5t4 antibodies and anti-5t4/calicheamicin conjugates: Chimeric and humanized anti-5T4 antibodies and antibody/drug conjugates and methods for preparing and using the same....

20060088526 - Humanized anti-cd3 specific antibodies: Novel aglycosylated antibodies having a binding affinity for the CD3 antigen complex are of value for use in therapy, particularly in immunosuppression....

20060088525 - Therapeutic binding molecules: A molecule comprising at least one antigen binding site, comprising in sequence the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-Ile-Ile-His (NYIIH), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) and said CDR3 having the amino acid sequence Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT); e.g. further comprising...

20060088524 - Tissue factor compositions and methods: Tissue Factor (natural or recombinant truncated) can be incorporated into stable, soluble nanoscale particles so that activity is maintained. These particles can be used as a reagent in prothrombin clotting time assays or they can be used in therapeutic compositions for use in humans or animals. Therapeutic settings can include...

20060088529 - Bispecific monoclonal antibodies to il-12 and il-18: A bispecific monoclonal antibody is described which comprises two moieties, one of which comprises an antigen-binding region which is specific for either the IL-12Rβ1 or the IL-12Rβ2 subunit of an IL-12 receptor, and the other of which comprises an antigen-binding region which is specific for either the IL-18R or the...

20060088528 - Methods and compositions for treating alzheimer's disease: The present invention relates to the treatment, diagnosis, and prophylactic prevention of Alzheimer's disease. More specifically, the present invention relates to methods and compositions for preventing the endocytosis and cellular internalization of integral membrane amyloid precursor protein (APP) and its subsequent catabolism by blocking or interfering with the association or...

20060088530 - Photodynamic therapy treatment for eye disease: This invention discloses methods, kits, and instructions to treat neovasculature diseases of the eye through the administration of a targeted photosensitizing agent and subsequent exposure to light of specific wavelength sufficient to photoactivate photosensitizing agent. The photosensitizing agent is bound to a composition that mediates site specific delivery to a...

20060088531 - Human antibodies against human glycoprotein vi and their use: Specific binding members directed to human glycoprotein VI (GPVI), in particular human antibodies, may employ the antibody VH and/or VL domain of the scFv fragment herein termed 10B12 or one or more complementarity determining regions (CDRs) of the 10B12 heavy chain variable (VH) and/or light chain variable (VL) domains, especially...

20060088532 - Lymphatic and blood endothelial cell genes: The invention provides polynucleotides and genes that are differentially expressed in lymphatic versus blood vascular endothelial cells. These genes are useful for treating diseases involving lymphatic vessels, such as lymphedema, various inflammatory diseases, and cancer metastasis via the lymphatic system....

20060088533 - Methods of treating inflammatory bowel disease: Methods for treating intestinal inflammation by inhibiting Clostridium difficile toxin B-mediated activation of the epidermal growth factor receptor or by inhibiting Clostridium difficile toxin B-mediated activation of the extracellular signal-regulated kinase 1/2 are described....

20060088534 - Human anti-factor ix/ixa antibodies: The invention provides for the isolation, identification, synthesis, expression and purification of antibodies reactive with factor IX (FIX)/factor IXa (IXa). In particular aspects, the invention provides human antibodies reactive with the human FIX Gla domain. The invention further provides compositions especially pharmaceutical compositions, articles of manufacture, and methods of inhibiting...

20060088535 - Method for enhancing long-term memory in a subject and uses thereof: The present invention provides for a method to enhance long-term memory in a subject whose cAMP-responsive gene expression is repressed due to binding of a cAMP-response-element-binding-protein-2 to a protein or a DNA associated with cAMP-responsive gene expression, or both, which comprises administering to the subject a compound capable of interfering...

20060088540 - Antagonists and methods for inhibiting angiogenesis: The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured collagen but not to native triple helical forms of the collagen. Antagonists of the invention can target, for example, denatured collagens type-I, type-II, type-III, type-IV, type-V and combinations...

20060088541 - Epha2 as a therapeutic target for cancer: The present invention is directed to compounds and methods for the treatment of cancer. The compounds of this invention have specificity for EphA2, an epithelial cell tyrosine kinase that is overexpressed in metastatic tumor cells. The compounds used in accordance with this invention may be provided in a pharmaceutical composition...

20060088539 - Modified antibodies to prostate-specific membrane antigen and uses thereof: Modified antibodies, or antigen-binding fragments thereof, to the extracellular domain of human prostate specific membrane antigen (PSMA) are provided. The modified anti-PSMA antibodies, or antigen-binding fragments thereof, have been rendered less immunogenic compared to their unmodified counterparts to a given species, e.g., a human. Pharmaceutical compositions including the aforesaid antibodies,...

20060088538 - Monoclonal antibody and gene encoding the same, hybridoma, pharmaceutical composition, and diagnostic reagent: A novel human monoclonal antibody specifically recognizing cancer cells such as non-small cell lung cancer, pancreatic cancer and gastric cancer cells is produced by hybridomas which are obtained by fusing lymphocytes derived from a cancer tissue of a cancer patient with mouse myeloma cells. An anti-cancer drug is obtained by...

20060088537 - Protein involved in cancer: The present invention relates to new uses of a protein (NKCC1) in the diagnosis, screening, treatment and prophylaxis of breast, lung and/or pancreatic cancer. The invention also provides compositions comprising the protein, including vaccines, antibodies that are immunospecific for the protein and agents which interact with or modulate the expression...

20060088536 - Therapeutic drug using antibody-presenting hollow protein nanoparticles and hollow protein nanoparticles: The invention provides a therapeutic drug that uses hollow protein nanoparticles displaying an antibody against a specific cell or specific tissue. The effectiveness of the drug has been proved by animal testing. The invention also provides a therapeutic method using such a drug. In a drug according to the present...

20060088542 - Imidazoquinoline adjuvants for vaccines: The invention relates to the fields of vaccines, vaccine adjuvants, molecular biology and immunology, and generally relates to adjuvants and nucleic acid immunization techniques. More specifically, the invention relates to certain adjuvant compositions, and to vaccine and/or nucleic acid immunization strategies employing such compositions....

20060088544 - Methods of preparation and composition of peptide constructs useful for treatment of autoimmune and transplant related host versus graft conditions: Peptide constructs including a first peptide segment which includes an amino acid sequence associated with autoimmune disease, asthma, allergy or xeno- or allograft transplantation rejections bonded directly or via a linker or spacer to a second peptide which binds to T cells and which will redirect the immune response from...

20060088543 - Use of passive myostatin immunization: A method to alter the phenotype of animals, e.g., avians, which employs passive and active immunization is provided....

20060088545 - Use of inhibitors of the protease of the human immunodeficiency virus (hiv) to block cell migration and/or invasion, tissue infiltration and oedema for the therary of diseases associated therewith: The present invention relates to a method to block the invasion of normal, neoplastic inflammatory or immune cells, tissue infiltration, and/or oedema formation through inhibition or modulation of molecules and proteolytic enzymes such as—but not exclusively—MMPs, for the therapy of all diseases whose pathogenesis is related to the above processes,...

20060088546 - Antigens for raising an immune response against rickettsieae and ehrlichieae pathogens: The present invention relates to the identification of polypeptides which are useful for raising an immune response against Ehrlichieae and Rickettsieae pathogens when administered into a subject. These polypeptides, and polynucleotides encoding therefor, can be used in various strategies for preventing or treating Ehrlichieae and Rickettsieae infections....

20060088547 - Expression, purification and uses of a plasmodium falciparum liver stage antigen 1 polypeptide: In this application is described the expression and purification of a recombinant Plasmodium falciparum (3D7) LSA-NRC polypeptide. The method of the present invention produces a highly purified polypeptide which is useful as a vaccine and as a diagnostic reagent....

20060088548 - Chimeric peptides as immunogens, antibodies thereto, and methods for immunization using chimeric peptides or antibodies: The invention provides a chimeric peptide or mixture of chimeric peptides that can be formulated as an immunizing composition and used in a method for immunization of a mammal against an internal peptide cleavage product derived from a precursor or mature protein, for which the peptide cleavage product and the...

20060088549 - Chimeric virus vaccine: The present invention provides an immunogenic composition comprising: (a) an isolated recombinant chimeric human rhinovirus, wherein the recombinant chimeric human rhinovirus comprises (i) a nucleic acid having a nucleotide sequence of a human rhinovirus encoding at least a portion of a human rhinovirus capsid; (ii) a heterologous nucleic acid having...

20060088550 - Gastric inhibitory polypeptide (gip) antigen arrays and uses thereof: The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The present invention provides, inter alia, a composition comprising a virus-like particle (VLP) and at least one antigen, wherein said antigen is a GIP protein or a GIP fragment linked to the VLP respectively....

20060088551 - Functional fragments of hiv-1 vpr protein and methods of using the same: Conjugated compositions comprising a fragment of HIV-1 Vpr or a non-HIV-1 Vpr protein conjugated to a therapeutic compounds and methods of using the same to deliver therapeutic compounds to a cell's nucleus or for the preparation of drug delivery particles are disclosed. Functional fragments of HIV-1 Vpr and functional non-HIV-1...

20060088552 - Method for inhibiting cell death, cell death inhibitor, and remedy for disease caused by cell death containing the cell death inhibitor: A method according to the present invention for inhibiting cell death includes administrating an anion channel-forming peptide to cells under lactacidosis. The anion channel-forming peptide forms an anion channel on a cell membrane artificially. A cell death inhibitor according to the present invention contains the anion channel-forming peptide. Some of...

20060088553 - Medicament for the treatment of diseases due to infection by neisseria meningitidis: A medicament for the treatment or prevention of diseases due to infection by Neisseria meningitidis, characterized in that it comprises glycoconjugates and/or lipooligosaccharides (LOS) included in outer membrane vesicles, blebs, lipid layers, liposomes and/or killed or commensal bacteria with cross-reactive antigens to Neisseria meningitidis of the serogroup A, B, C,...

20060088554 - Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine: The present invention describes derivatized polysaccharide-protein conjugates, a composition comprising one or more of such derivatized polysaccharide-protein conjugates and methods of immunizing human patients with the same. The derivatized polysaccharide-protein conjugates are purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W-135, and Y, derivatized chemically activated and selectively attached...

20060088555 - Flagellin-based adjuvants and vaccines: The present invention provides adjuvants, vaccines and related methods that are useful in eliciting immune responses, particularly immune responses against tumor antigens. We discovered that flagellin is capable of inhibiting tolerance when it is administered in conjunction with a tolerogenic antigen. This effect is likely mediated by the ability of...

20060088557 - Novel skin care formulation: Skin moisturizing formulations which can be administered in the bath or shower, depositing a thin layer of moisturizing agents on application, which is not rinsed off but remains to protect the skin from drying, resulting in smoother, softer skin feel; the formulations comprising polyvalent metal cations and fatty acids, which...

20060088556 - Topical formulation and use of buspirone: A liquid or semi-solid topical formulation of buspirone, when applied to human epidermis in vitro (following methods defined herein), results in a transepidermal flux rate of buspirone (individual or mean data) in one or more of the following ranges: 0.1 to 1.1 μg/cm2/hour as assessed over 5 hours following application;...

20060088558 - Vitamin e tpgs fluid concentrate comprising a low percentage of water: A liquid Vitamin E TPGS concentrate composition is provided, the concentrate having a significantly higher percentage of TPGS per unit volume than traditional liquid TPGS formulations while providing the TPGS in a liquid form that can be used in softgels or mixed with water to produce desired concentrations for commercial...

20060088562 - Cosmetic compositions: A cosmetic composition having improved transfer resistance comprising: a) from about 0.1-60% by weight of trimethylated silica, b) from about 0.1-60% by weight of a volatile solvent having a viscosity of 0.5 to 100 centipoise at 25° C., c) 0.1-60% by weight of a nonvolatile oil having a viscosity of...

20060088560 - Cosmetic use of mangiferin: The present invention concerns a cosmetic use of mangiferin, or one of its isomers or derivatives, in particular a plant extract containing mangiferin, for example a leaf extract of Aphloia or Mangifera, for preventing and/or reducing the effects caused by heat stress on the skin, lips or hair....

20060088559 - Method for producing anis alcohol: The present invention relates to a method for the preparation of anisalcohol (methoxybenzyl alcohol) by hydrogenation of anisaldehyde (methoxybenzaldehyde) in the presence of Raney nickel and a basic additive, the use of the anisalcohol and hygiene or care products containing anisalcohol....

20060088561 - Pharmaceutical composition for topical application: A pharmaceutical or cosmetic carrier or composition for topical application characterized by rheological properties which render the carrier or composition semi-solid at rest and a liquid upon application of shear forces thereto. The composition or carrier are prepared by mixing 1-25 percent of a solidifying agent and 75-99 percent of...

20060088564 - Synergistic and residual pesticidal compositions containing plant essential oils with enzyme inhibitors: Synergistic and residual pesticidal compositions containing synergistic and residual mixtures of plant essential oils in admixture with enzyme inhibitors, with or without other compounds not previously used as active ingredients in pesticidal formulations. In addition, the present invention is directed to a method for controlling pests by applying a pesticidally-effective...

20060088563 - Use of spray adjuvant to enhance the movement of pesticides through plant canopies to the target: Pesticide compositions and methods of using the compositions for killing, inhibiting or repelling pests are disclosed. The pesticide compositions are admixtures of at least one pesticide and a repellent adjuvant. The retention of the pesticide compositions on the foliage of plants is reduced, so that the composition facilitates the penetration...

20060088565 - Device having osteoinductive and osteoconductive properties: The present invention relates to a device having osteoinductive and osteoconductive properties in vivo comprising a carrier containing calcium phosphate and an osteoinductive protein, wherein said carrier is homogenously coated with said protein. Moreover, the present invention relates to a method for the production of a device having osteoinductive and...

20060088568 - Implantation of tissue bulking devices: One or more tissue bulking devices are implanted to bulk a structure within a patient. The tissue bulking devices may be implanted between the structure and an adventitial layer that at least partially covers the structure, or within the adventitial layer. In some embodiments, the structure is a luminal wall...

20060088566 - Method of controlling drug release from a coated medical device through the use of nucleating agents: A coated medical device have a drug and a nucleating agent thereon. Also provided are methods of increasing or decreasing the size of drug particles on a coated substrate through the use of nucleating agents to thereby increase or decrease the release rate of the drug from the coated substrate....

20060088567 - Method of manufacturing a medical device having a porous coating thereon: Methods of manufacturing drug-coated medical devices having a porous coatings thereon. The pores are created by solid particle additives added to a mixture comprising a solvent, a drug, and a polymer to create a suspension, which is applied to the medical device. The method includes adding a surfactant to the...

20060088569 - Sheet for guiding regeneration of mesenchymal tissue and production method thereof: To provide a sheet for guiding regeneration of mesenchymal tissue having improved formability, strength, absorbability and efficiency, the sheet is produced by steps of containing a culture medium in a surface of a porous sheet produced by freezing a bioabsorbable polymer material dissolved with an organic solvent and drying it,...

20060088570 - Systems and methods for applying cross-linked mechanical barriers: A delivery device applies a biocompatible and biodegradable barrier material to a tissue region, e.g., to seal a vascular puncture site. The material comprises two liquid components, which are pre-packaged in individual dispensers. Upon mixing, the liquid components cross-link to create a barrier matrix. A holder attaches to the delivery...

20060088572 - Angiotensin-(1-7) eluting polymer-coated medical device to reduce restenosis and improve endothelial cell function: Medical devices with polymer coatings designed to control the release of angiotensin-(1-7) receptor agonists from medical devices are disclosed. The present application also discloses providing vascular stents with angiotensin-(1-7) receptor agonist-containing controlled-release coatings. Methods for treating or inhibiting post-stent implantation restenosis as well as improving vascular endothelial function in patients...

20060088571 - Biocompatible and hemocompatible polymer compositions: Biocompatible coatings for medical devices are disclosed. Specifically, polymer coatings designed to control the release of bioactive agents from medical devices in vivo are disclosed. The present application also discloses providing vascular stents with controlled release coatings and related methods for making these coatings. Additional embodiments of the present invention...

20060088573 - Composition having action preventing or alleviating symtoms or diseases due to aging of blood vessels: A composition and food or beverage containing arachidonic acid or a compound having arachidonic acid as a component fatty acid and having an action preventing or alleviating symptoms or diseases due to aging of the blood vessels....

20060088575 - Homeopathic preparations of purified growth factors and purified growth hormones and associated carriers: A preparation comprising a homeopathic potency of a purified composition, such as insulin-like growth factor, insulin-like growth factor-1 (IGF-1), growth hormone, transforming growth factor (TGF), TGFβ1, fibroblast growth factor (FGF), FGF1, FGF2, GM-CSF, M-CSF, PDGFββ, nerve growth factor (NGF) and epidermal growth factor (EGF), is provided. The concentration of the...

20060088574 - Nutritional supplements: The invention provides nutritional supplements for an oral or enteral administration to humans, whether in satisfactory health, or having a medical condition. These supplements can provide humans with a complete, balanced nutrition in a bioavailable form, either as a food supplement or as a meal replacement, and preferably includes one...

20060088576 - Method for enhancing milk production: The present invention concerns a method of enhancing milk production by a ruminant that includes providing a feed that contains sorbitol and at least one additional feed component, and orally feeding the feed to the ruminant, the ruminant ingesting about 100 grams, or less, of sorbitol per day....

20060088578 - Biopolymeric membranes: This invention relates to a sheet membrane for repairing a damaged tissue. The membrane includes an isotropic layer of cross-linked biopolymeric fibers in which the fibers are 10 to 1,000 cm in length. This invention also relates to a method of making an isotropic layer of cross-linked biopolymeric fibers. The...

20060088577 - Process for manufacturing fibrin membranes and fibrin membranes obtained according to this process: A process for manufacturing a fibrin membrane from blood plasma that was partially depleted and subjected to coagulation by adding a solution of a physiological coagulating agent, leaving the mixture to stay until forming a gelatinous blood clot, and then dehydrating said blood clot to obtain a fibrous membrane, which...

20060088579 - Transdermal drug delivery systems: One aspect of the invention provides a transdermal delivery system including a drug formulated with a transport chaperone moiety that reversibly associates with the drug. The chaperone moiety is associated with the drug in the formulation so as to enhance transport of the drug across dermal tissue and releasing the...

20060088581 - Device for delivery of therapeutic agent: The invention provides a system for administering to or through the skin of the individual selected medicaments. The system includes an orthosis and a pad. The pad includes at least one delivery station suitable for containing the medicament. The pad may be positioned in a variety of configurations on the...

20060088580 - Hormone-containing transdermal therapeutic system with an active substance reservoir based on vinylacetate-vinylpyrrolidone copolymer with improved cohesion: A transdermal therapeutic system in patch form for the controlled delivery of active substances to the human or animal skin comprises a backing layer, an active substance-containing reservoir attached thereto and a detachable protective layer, is characterized in that the active substance-containing reservoir contains as main components thereof at least...

20060088583 - Artificial oxygen carrier containing preventive agents of methb formation: The present invention provides an agent containing L-tyrosine that prevents methemoglobin formation, and a vesicle comprising the above agent for preventing methemoglobin formation. More specifically, the present invention provides an oxygen infusion preparation suitable for long-term storage, which prevents an increase in methemoglobin content as a result of oxidation of...

20060088584 - Liposomal formulations of hydrophobic photosensitizer for photodynamic therapy: Pharmaceutical liposomal formulations are described for photodynamic therapy comprising a, hydrophobic porphyrin photosensitizer, a monosaccharide and one or more synthetic phospholipids, which are stable in storage especially through freeze-drying process. The liposomal formulations provide therapeutically effective amounts of the photosensitizer for intravenous administration. In particular derivatives of chlorins and bacteriochlorins,...

20060088582 - Phosphatidyl oligo glycerins and structural analogs: This invention relates to novel structural analogs to phosphatidyl oligo glycerins. These compounds can be used, in particular, for producing liposomes having a long circulation time with or without thermolability. The invention also relates to liposomes containing compounds of the aforementioned type and to medicament compositions....

20060088585 - Dosage forms having a microreliefed surface and methods and apparatus for their production: The present invention provides an edible dosage form that incorporates optical elements (e.g., printed patterns, microrelief gratings, and/or macrorelief gratings), capable of producing unique optical effects and images in order to enable a user to better identify and differentiate the dosage forms, as well as to improve the detection of...

20060088586 - Dosage forms having a microreliefed surface and methods and apparatus for their production: The present invention provides an edible dosage form that incorporates optical elements (e.g., printed patterns, microrelief gratings, and/or macrorelief gratings), capable of producing unique optical effects and images in order to enable a user to better identify and differentiate the dosage forms, as well as to improve the detection of...

20060088587 - Dosage forms having a microreliefed surface and methods and apparatus for their production: The present invention provides an edible dosage form that incorporates optical elements (e.g., printed patterns, microrelief gratings, and/or macrorelief gratings), capable of producing unique optical effects and images in order to enable a user to better identify and differentiate the dosage forms, as well as to improve the detection of...

20060088588 - Medication administering device and system: A suppository method and device for taking or administering “over-the-counter” and prescription including a capsule formed by a dissolvable material and specific quantity of a predetermined medication stored or storable in the capsule and sterilized light-resistant, moisture-proof foil peel-back packet for storage and packaging prior to use, which may be...

20060088589 - Reinforced absorbable multilayered hemostatic wound dressing: The present invention is directed to a reinforced absorbable multilayered hemostatic wound dressing comprising a first absorbable nonwoven fabric, a second absorbable woven or knitted fabric, thrombin and fibrinogen....

20060088590 - Non-blooming gelatin and non-gelatin formulations: A non-blooming plasticizer composition and methods of using the composition are described herein. The composition is a mixture of sorbitol and sorbitan wherein the ratio of sorbitan and sorbitol is between about 0.40 and about 1.2 by weight, more preferably from about 0.45-0.50 to about 0.70 by weight, wherein the...

20060088593 - Dosage forms having a microreliefed surface and methods and apparatus for their production: The present invention provides an edible dosage form that incorporates optical elements (e.g., printed patterns, microrelief gratings, and/or macrorelief gratings), capable of producing unique optical effects and images in order to enable a user to better identify and differentiate the dosage forms, as well as to improve the detection of...

20060088594 - Highly compressible controlled delivery compositions of metformin: Highly compressible controlled delivery compositions of metformin or salts thereof and the process of making the same are disclosed. Metformin is granulated with a binder and further dispersed in a rate-controlling matrix that results in increased hardness and decreased friability thereby effectively solving compressibility difficulties arising for Metformin formulations....

20060088592 - Oral formulation for delivery of poorly absorbed drugs: A composition for oral delivery of a poorly absorbed drug is disclosed. The composition includes the drug, an enhancer for increasing absorption of the drug through the intestinal mucosa, a promoter, which alone does not increase absorption of the drug through the intestinal mucosa, but which further increases the absorption...

20060088591 - Tablets from a poorly compressible substance: A solid composition suitable for forming into a tablet includes a pharmaceutically active substance in an amount sufficient to provide a therapeutic effect when administered; from about 0.2 to about 15 weight %, based on the total weight of the composition, of a water-soluble preparation of a fat-soluble vitamin; and...

20060088595 - Dispersant for sustained release preparations: The present invention provides a bilayer dispersing agent for a sustained-release preparation, which contains a non water-soluble solvent and an aqueous solvent, and a sustained-release preparation wherein a microcapsule containing a physiologically active substance is dispersed in the aforementioned dispersing agent. When this preparation is subcutaneously administered, the initial release...

20060088596 - Solubilizing a drug for use in a coating: A method for the provision of a coating on an implantable medical device results in a medical device having a bio-absorbable coating. The coating includes a bio-absorbable carrier component. In addition to the bio-absorbable carrier component, a dissolved therapeutic agent component can also be provided. The coated medical device is...

20060088597 - Agent delivery system: A delivery vehicle including a mixture of: a) an effective amount of an expander activatable by a wetting agent and, b) a treatment agent. The expander and treatment agent intermingled and compressed so as to form a substantially solid delivery vehicle. The solid delivery vehicle, on exposure to a volume...

20060088599 - Amino functionalized ormosil nanoparticles as delivery vehicles: Provided are amino functionalized ORMOSIL nanoparticles. Also provided are compositions comprising such particles and compositions in which the nanoparticles are complexed to polynucleotides. The complexing of polynucleotides to the amino functionalized ORMOSIL nanoparticles protects the polynucleotides from environmental damage. These complexes can be used for delivery of polynucleotides to cells....

20060088598 - Intravenous composition, process for producing the same and preparation thereof: A composition for intravenous injection, which gradually decomposed instead of fat particles, has sufficient sustained release effects, has an excellent encapsulation ratio of lipid-soluble agents, and has such sustained release effects at lesion sites; a production method thereof; and a preparation containing the composition. The composition for intravenous injection is...

20060088600 - Treatment for dry eye syndrome: A novel formulation for the treatment of the many underlying inflammatory processes that cause dry eye syndrome. In particular, the formulation, which is orally administered includes the optimal blend of omega-3 and omega-6 essential fatty acids, and nutrient cofactors necessary to enhance the metabolic conversion associated with the tear-specific series...

20060088601 - Synthetic bone substitute material: The invention includes a synthetic bone substitute material suitable for use as a replacement for cancellous bone in a bone graft composition, the material comprising a reticulated framework of interconnecting bioceramic struts defining an interconnecting interstitial void volume, and a solid non-porous composition substantially filling the interstitial void volume and...

20060088602 - Electromagnetic field regulating compositions: A cosmetic or pharmaceutical emulsion composition that is topically applied to the skin to protect it against damage caused by electromagnetic field generated from everyday appliances such as televisions, computers and cellular phones. The compositions contain ambient electromagnetic wave dampening effective amounts of at least one single domain magnet as...

20060088603 - Compositions and methods for nutrition supplementation: The present invention relates to compositions comprising various vitamins and minerals and methods for using these compositions for nutritional supplementation in, for example, pregnant or lactating subjects....

20060088604 - Therapeutic ointment for treating dermatological infections and method of using same: A therapeutic ointment that includes (a) a skin protecting agent, (b) an anti-inflammatory agent, and (c) an antibiotic composition, and a method of using the ointment to treat mammals suffering from dermatological infections....

20060088605 - Preservative compositions for materials and method of preserving same: Preservative composition for various materials and method of preserving the same is disclosed. The preservative composition includes at least one silane-containing material and at least one hydrocarbon solvent containing molecules of at least five carbon atoms....

20060088606 - Methods and compositions for use in perfusion applications: Methods and compositions for use in perfusion applications are provided. In the subject methods, a subject or derivative thereof, e.g. isolated organ or tissue, is infused, perfused and/or transfused with at least two fluid compositions. The first fluid composition is a non-naturally occurring biological buffer free plasma-like solution and the...

20060088607 - Nutritional supplement compositions: Dietary supplement compositions containing one or more compounds such as arginine, selenium, calcium, calcium sources, morphine precursors (e.g., reticuline), morphine, and morphine-6β-glucuronide are provided....

20060088609 - Compositions containing cotinus coggygria extract and use thereof on mucosal tissues: The present invention relates to a method of enhancing the mucus production of mucosal tissue by administering to mucosal tissue in need of such enhancement a composition containing a safe and effective amount of Cotinus coggygria extract....

20060088608 - Compositions containing cotinus coggygria extract and use thereof on skin and mucosal tissues: The present invention relates to a method of enhancing the elasticity or structural integrity of skin or mucosal tissue by administering to skin or mucosal tissue in need of such enhancement a composition containing a safe and effective amount of Cotinus coggygria extract....

20060088610 - Anti-inflammatory cranberry flavonol extract preparations: The present invention is directed to extracts of cranberries (Vaccinium macrocarpon) comprising either mixed flavonols that are substantially free of anthocyanins and proanthocyanidins or a purified cranberry flavonol compound, including myricetin-3-β-xylopyranoside, quercetin-3-β-glucoside, quercetin-3-α-arabinopyranoside, 3′-methoxyquercetin-3-α-xylopyranoside, quercetin-3-O-(6″-p-coumaroyl)-β-galactoside, and quercetin-3-O-(6″-benzoyl)-β-galactoside. The present invention also embodies the use of those extracts, as well as...

20060088611 - Morinda citrifolia-based formulations and methods for weight management: The present invention relates to formulations and methods for weight management utilizing processed Morinda citrifolia products or extracts. Specifically, the present invention relates to formulations, which may be used for weight loss, regulating gastric motility and regulating plasma levels of cholecystokinin....

20060088612 - Composition for treatment of topical infection and methods of making and using same: Compositions and methods for the prevention and treatment of topical infections using essential oil or extract from Minthostachys mollis (Peperina) or other herbs of the family Lamiaceae, or any combination of its individual chemical components and an acceptable carrier are disclosed....

20060088613 - Simmondsin for use as angiogenesis inhibitor: The present invention relates to the use of an active component derived from jojoba, and in particular a simmondsin, steroisomeric forms, racemic mixtures, metabolites, pharmaceutically acceptable esters or salts thereof, or mixtures thereof for the manufacture of a medicament for inhibiting angiogenesis and for the manufacture of a medicament for...

20060088614 - Compounds, compositions and methods for treating neuropsychiatric disorders: Acetyl-L-carnitine (ALCAR) and L-carntine (LCAR) are nutraceuticals with indications in treating a variety of mental health disorders. A metabolomics-guided bioprocess method is presented to enhance ALCAR and LCAR formation in germinating plant seeds. Metabolic fluxes are manipulated by germination in bioreactors to increase oxygen availability as well as provide an...

20060088616 - Compositions containing malva sylvestris extract and use thereof on mucosal tissues: The present invention relates to a method of enhancing the mucus production of mucosal tissue by administering to mucosal tissue in need of such enhancement a composition containing a safe and effective amount of Malva sylvestris extract....

20060088615 - Compositions containing malva sylvestris extract and use thereof on skin and mucosal tissues: The present invention relates to a method of enhancing the elasticity or structural integrity of skin or mucosal tissue by administering to skin or mucosal tissue in need of such enhancement a composition containing a safe and effective amount of Malva sylvestris extract....

20060088617 - Chocolate composition and method for benefiting the cardiovascular system: A medicinal or food supplement composition comprised essentially of dark chocolate less most of the fat and sugar and with high levels of chocolate flavonoids, and a method by which the composition is consumed by a person or other mammal in specified doses per day over a period of time,...

20060083679 - Agents with selective k-opioid receptor affinity: Compounds and compositions that are salvinorin A and salvinorin B derivatives that demonstrate selectivity and/or potency for the k-opioid receptor (KOR), allowing for their use as medicines, as well as chemical probes (both radiolabeled and cold) for fields utilizing the techniques of radiolabeled binding assays....

20060083681 - Compounds for myocardial perfusion imaging: The present disclosure is directed to compounds comprising imaging moieties and their use for diagnosing certain disorders....

20060083680 - Diphenyl ether derivatives and their use for imaging serotonin transporters: This invention relates to diphenyl ether derivatives and their use in imaging of Serotonin Transporters (SERTS). The present invention also provides diagnostic compositions comprising the compounds of the present invention, and a pharmaceutically acceptable carrier or diluent. The invention further provides a method of imaging SERTS, comprising introducing into a...

20060083682 - Novel methods of cancer therapy targeted against a cancer stemline: Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer treatment and reduce the likelihood of clinical relapse after treatment....

20060083678 - Radio-labeled compounds, compositions, and methods of making the same: 18F radio-labeled compounds, methods of making the radio-labeled compounds, and applications of the same are disclosed....

20060083676 - Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands: In a preferable embodiment, X represents O; R1 represents C1-6alkyl; cycloC3-12alkyl or (cycloC3-12alkyl)C1-6alkyl, wherein one or more hydrogen atoms in a C1-6alkyl-moiety or in a cycloC3-12alkyl-moiety optionally may be replaced by C1-6alkyloxy, aryl, halo or thienyl; R2 represents hydrogen; halo; C1-6alkyl or amino; R3 and R4 each independently represent hydrogen...

20060083677 - Solid-phase fluorination of benzothiazoles: The invention provides a process for the production of an 18F-labelled tracer which comprises treatment of a solid support-bound precursor of formula (I) SOLID SUPPORT-LINKER-X-TRACER (I) wherein X is a group which promotes nucleophilic substitution at a specific site on the attached TRACER and the TRACER is of formula (A)....

20060083683 - Antibody fragment-polymer conjugates and uses of same: Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also...

20060083684 - Method of radio-labelling biomolecules: A method of radio-labelling a biomolecule comprising contacting the biomolecule with a source of radionuclide, such as technetium, in the presence of a weak transfer ligand and optionally subsequently passing the mixture through a size-exclusion filtration process. Also claimed are kits comprising such novel compositions, especially lactoferrin coupled to chemotherapeutic...

20060083685 - Opioid metallopeptide compositions and methods: Metallopeptides and metallopeptide combinatorial libraries specific for opioid receptors are provided, for use in biological, pharmaceutical and related applications. The metallopeptides and combinatorial libraries are made of peptides, peptidomimetics and peptide-like constructs, in which the peptide, peptidomimetic or construct is conformationally fixed in a biologically active configuration specific for one...

20060083686 - Therapeutic agent for ulcerative colitis: Disclosed are pharmaceutical compositions of treatment for a patient with ulcerative colitis comprising a drug which can selectively kill Fusobacterium varium cells, or a drug which can neutralize the toxin produced by Fusobacterium varium cells, a method for screening such a drug, a method for treating a patient with the...

20060083687 - Method and system of obtaining improved data in perfusion measurements: A method of deriving blood perfusion indices for a region of interest (ROI) of a subject, comprising the steps of administering a contrast agent to the subject during a dynamic imaging scan, converting signal intensity data from raw images of the scan into contrast agent concentration data, deriving parameters from...

20060083689 - Contrast enhancement agent for magnetic resonance imaging: Imaging agents for magnetic resonance imaging are disclosed. Methods of monitoring angiogenesis and the growth and remission of tumor tissue are also disclosed. Methods of monitoring blood clot formation and dissolution are additionally disclosed. Methods of monitoring wound healing are further disclosed. A kit for obtaining an image of a...

20060083688 - Optical determination of glucose utilizing boronic acid adducts: The present invention concerns an improved optical method and optical sensing device for determining the levels of polyhydroxyl-substituted organic molecules in vitro and/or in vivo in aqueous media. The range of detection is between about 400 and 800 nm. In particular, a sensory devise is implemented in a mammal to...

20060083690 - Less abusable pharmaceutical preparations: The present invention is directed to pharmaceutical compositions of psychoactive drugs having a reduced potential for abuse and methods of reducing the potential for abuse of dosage forms of prescription psychoactive drugs....

20060083692 - Combination of formoterol and a tiotropium salt: A medicament containing, separately or together, (A) formoterol or a pharmaceutically acceptable salt thereof or a solvate of formoterol or said salt and (B) a tiotropium salt of a pharmaceutically acceptable acid, for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease....

20060083691 - Intranasal opioid compositions, delivery devices and methods of using same: The present invention relates to pharmaceutical compositions comprising opioids and a liquid nasal carrier, to delivery devices comprising such compositions, and to methods of manufacture and use of such compositions....

20060083693 - Stable pharmaceutical solution formulations for pressurised metered dose inhalers: An aerosol solution composition for use in an aerosol inhaler comprises an active material, a propellant containing a hydrofluoroalkane, a cosolvent and optionally a low volatility component to increase the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler. The composition is stabilized by using...

20060083694 - Multi-component particles comprising inorganic nanoparticles distributed in an organic matrix and processes for making and using same: Multi-component particles comprising inorganic nanoparticles distributed in an organic matrix and processes for making and using same. A flowing aerosol is generated that includes droplets of a precursor medium dispersed in a gas phase. The precursor medium contains a liquid vehicle and at least one precursor. At least a portion...

20060083695 - Sweetener composition: Storing monatin or a salt thereof in the presence of a radical scavenger and/or in a UV light-shielding container is effective for preventing the decomposition of monatin or a salt thereof by exposure to ultraviolet light, particularly under acidic conditions. Sweetener compositions which contain monatin or a salt thereof and...

20060083696 - Composition cosmetique comprenant un polymere acrylique: an organic solvent phase comprising at least one first organic solvent, the said phase being free of lower monoalcohol containing from 1 to 5 carbon atoms or of C3-C4 ketone, or containing them in a weight content, relative to the total weight of the composition, of less than or equal...

20060083698 - Photostable photoprotective compositions comprising dibenzoylmethane and amide oil compounds and a compound that accepts the excited triplet level energy of said dibenzoylmethane(s): Topically applicable, improvedly photostabilized, photoprotective cosmetic/dermatological compositions contain (i) an effective UV-screening amount of at least one dibenzoylmethane sunscreen and an effective photostabilizing amount of (ii) at least one oil containing at least one amide structural unit and (iii) at least one compound accepting the excited triplet level energy of...

20060083699 - Photostable photoprotective compositions comprising dibenzoylmethane and bis-resorcinyl triazine compounds and a compound that accepts the excited triplet level energy of said dibenzoylmethane(s): Topically applicable, improvedly photostabilized, photoprotective cosmetic/dermatological compositions contain (i) an effective UV-screening amount of at least one dibenzoylmethane sunscreen and an effective photostabilizing amount of (ii) at least one bis-resorcinyl triazine compound and (iii) at least one compound accepting the excited triplet level energy of said at least one dibenzoylmethane...

20060083697 - Topical skin lightening cream: The present invention is a novel topical composition for the treatment of non-congenital dermal blemishes comprising, hydroquinone wherein the concentration of hydroquinone is not less than 2 percent and not more than 12 percent, tretinoin wherein the concentration of tretinoin is not less than 0.01 percent and not more than...

20060083700 - Use of a novel phytonutrient rich bioactive concentrate (ri-activetm) for the prevention and treatment of cardiovascular disease, diabetes and other health disorders: The present invention is generally related to the discovery of the use of a novel composition (Ri-Active™), containing a concentrate of the bioactives, micronutrients and antioxidants present in the unsaponifiable fraction of rice bran oil or rice germ oil, in the prevention and treatment of health disorders. The novel use...

20060083701 - Nail enamel compositions, related methods, and a two component kit for painting the nails: A nail enamel composition comprising, by weight of the total composition, about 10-95% solvent, and 5-95% of a film forming polymer having a glass transition temperature in the range of 5 to 90° Centigrade, and containing about 2 to 29% by weight of the total polymer of at least one...

20060083703 - Hair conditioning composition comprising polyol esters containing alkyl chains: A hair conditioning composition comprising polyol esters containing alkyl chains and a gel matrix. The composition of the present invention can provide improved conditioning benefits such as smooth feel and reduced friction to both damaged hair and non-damaged hair, while providing other benefits such as slippery and slick feel on...

20060083704 - Hair conditioning composition comprising high internal phase viscosity silicone copolymer emulsions: A hair conditioning composition comprising silicone copolymer emulsions with an internal phase viscosity of greater than about 120×106 mm2/sec and a gel matrix. The composition of the present invention can provide improved conditioning benefits such as smooth feel and reduced friction to both damaged hair and non-damaged hair, while providing...

20060083705 - Vinyl lactam/vinyl carbazole copolymers: A copolymer of a vinyl lactam and vinyl carbazole useful in personal care compositions....

20060083706 - Haircare composition comprising at least one electrophilic monomer and micro- or nanoparticles of at least one solid lubricant: Disclosed herein is a haircare composition comprising, in a cosmetically acceptable medium, at least one electrophilic monomer and micro- or nanoparticles of at least one solid lubricant....

20060083702 - Hair fiber treating method: The present disclosure relates to a hair fiber treatment method without a hair fixing step. This method includes applying a reducing composition containing no ceramide onto hair fibers, and raising the temperature of the hair fibers with a heating iron at a temperature of at least 60° C. The reducing...

20060083708 - Composition using mineral salts for cosmetic or therapeutic treatment: A cosmetic and tissue cleansing composition including mineral salts, preferably Dead Sea Mineral Salts, Tea Tree Extract and Urea as an effective agent to minimize the effect of itching on the skin from a condition caused by psoriasis. In another form, the composition can be used as an exfoliating or...

20060083707 - Facial pack and bathing compositions based on hwangto (korean loess) and preparation thereof: Disclosed are a facial pack composition and a bathing composition based on loess, and methods for preparing the same. The bathing composition makes a user feel refreshed, prevents arteriosclerosis and fat accumulation in human bodies, is useful for the treatment of maturating diseases such as dermatophytosis and dermatitis and stimulates...

20060083710 - Process for making antimicrobial polymer articles: This invention relates to a process for making articles antimicrobial and odor inhibiting, which comprises using vacuum deposition and electron beam techniques to graft amino-reactive functional groups onto polymeric material which the article comprises, followed by contacting the polymeric material with a chitosan solution....

20060083709 - Sustained release air freshening device: This invention relates to a device that provides controlled release of a fragrant or deodorizing substance: the fragrant or deodorizing substance being solublized with an appropriate carrier solvent within a polymeric matrix. The layers function as protective barriers, semi-permeable membranes, fragrance reservoirs, and adhesives. The device is capable of delivering...

20060083711 - Methods and products related to the intracellular delivery of polysaccharides: The invention relates, in part, to methods and compositions for the intracellular delivery of polysaccharides. In particular, the methods and compositions relate to the intracellular delivery of glycosaminoglycans, such as heparin. The invention in other aspects relates to the use of glycosaminoglycans for the treatment of proliferative disorders, such as...

20060083712 - Methods and compositions for the repair and/or regeneration of damaged myocardium: Methods, compositions, and kits for repairing damaged myocardium and/or myocardial cells including the administration of stem cells, such as adult stem cells, optionally with cytokines are disclosed and claimed....

20060083713 - Methods of using a human il-17 related polypeptide to treat disease: Methods are provided for the treatment or prevention of atherosclerosis, allergic autoimmune diseases, endothelial cell apoptosis, allograft vasculopathy, hypertension, congestive heart failure, ischemia/reperfusion injury, type 1 diabetes, inflammation, immunodeficiencies, cancers, and infectious diseases by administering a human IL-17 related polypeptide and/or an antibody recognizing an epitope thereof to a patient...

20060083714 - Combination of a pde iv inhibitor and a tnf-alpha antagonist: The subject invention relates to therapeutic combinations and methods for the treatment of inflammatory conditions and diseases. Particularly the present invention relates to treatments and methods for PDE IV-related conditions and for TNF-alpha-related conditions using a combination of a PDE IV inhibitor and a TNF-alpha antagonist....

20060083715 - Interferon beta-like molecules for treatment of stroke: The present invention relates to use of interferon beta-like polypeptides for treatment of stroke or transient ischemic attach in a primate, preferably in a human. More particularly, the interferon beta-like polypeptides differs from the amino acid sequence of wild-type human IFNB (SEQ ID NO:2) in that at least one glycosylation...

20060083716 - Composition for delivering an agent to a target cell and uses thereof: The present invention provides a composition for delivering an agent to a target cell, comprising: (a) a microorganism that has, on its cell surface, at least one exogenous molecule that binds to an antigen on the surface of a target cell; and (b) an agent. The present invention further provides...

20060083717 - System and method for forming a non-ablative cardiac conduction block: A system forms a cardiac conduction block at a location in a heart of a patient, generally without substantially ablating cardiac tissue. The system includes a delivery system coupled to a source of material that is substantially non-ablative with respect to cardiac tissue but that substantially interrupts and thus blocks...

20060083718 - Novel therapy for lysosomal enzyme deficiencies: The present invention provides a therapeutic delivery system comprising an extracted yeast cell wall comprising beta-glucan, a payload trapping molecule and a payload molecule, wherein the payload molecule and the payload trapping molecule are soluble in the same solvent system wherein the payload molecule supplements the function of the deficient...

20060083722 - Methods and compositions for cell therapy: Improved methods of cell therapy are provided using cells and tissues that are histocompatible with a human or non-human mammal transplant recipient. The cells and tissues for transplant produced by the present invention exhibit a youthful state and can be committed to specific cell lineages to better infiltrate and proliferate...

20060083724 - Compositions for the treatment of femal sexual dysfunction: The compositions and methods disclosed herein are of use for the treatment of female sexual dysfunction. The disclosed compositions and methods pertain to topical formulations including at least three vasodilating agents that act by different physiological pathways, and at least one sensory or functional additive....

20060083723 - Novel microorganism strain gm-090 of lactobacillus fermentum and its use for stimulating ifn-y secretion and/or treating allergy: The present invention provides an isolated microorganism strain, Lactobacillus fermentum GM-090, which is found to be effective in stimulating IFN-γ secretion and/or treating allergy. The use of the Lactobacillus fermentum GM-090 in stimulating IFN-γ secretion and/or treating allergy is also provided....

20060083725 - Suppression of root and tuber disease: Methods are provided for suppressing bacterial and fungal disease in roots and tubers by treating the plant tissue, seed, and surrounding soil with Bacillus firmus bacteria....

20060083726 - Method for controlling insects of the order diptera using a bacillus thuringiensis strain: The invention provides a method for controlling insects of the Order Diptera by providing a Bacillus thuringiensis strain or variant thereof, or a spore or crystal of the Bacillus thuringiensis strain or variant thereof, and either contacting the insect with or administering to an animal the Bacillus thuringiensis strain or...

20060083719 - Fixed-dried red blood cells: Fixed-dried red blood cells (RBCs), and processes for preparing the same are disclosed. The red blood cells, upon reconstitution with distilled water or appropriate buffer: bind oxygen with native affinities, have partial deformability, present minimal thrombogenicity to platelets, and have oblated blood group antigens. The RBCs are preferably fixed by...

20060083721 - Injectable cross-linked polymeric preparations and uses thereof: A therapeutic composition for treatment of a body tissue which includes an aqueous solution of a cross-linked polymer being capable of: (i) maintaining a liquid state in storage at room temperature for at least 24 hours; and (ii) assuming a gel state following deposition within the body tissue. The therapeutic...

20060083720 - Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions: Adipose derived regenerative cells are used to treat patients, including patients with cardiovascular conditions, diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells, e.g., stem and/or progenitor cells, obtained from the adipose tissue to a patient. The methods may be...

20060083728 - Acellular matrix implant for treatment of cartilage lesions, injuries and defects: An acellular matrix implant for treatment of defects and injuries of articular cartilage, bone or osteochondral bone and a method for treatment of injured, damaged, diseased or aged articular cartilage or bone, using the acellular matrix implant implanted into a joint cartilage lesion in situ and a bone-inducing composition implanted...

20060083729 - Biocompatible tissue sealant for treatment of osteochondral and bone defects using an acellular matrix implant: An acellular matrix implant for treatment of defects and injuries of articular cartilage, bone or osteochondral bone and a method for treatment of injured, damaged, diseased or aged articular cartilage or bone, using the acellular matrix implant implanted into a joint cartilage lesion in situ and a bone-inducing composition implanted...

20060083730 - Method for treatment of osteochondral and bone defects using an acellular matrix implant: An acellular matrix implant for treatment of defects and injuries of articular cartilage, bone or osteochondral bone and a method for treatment of injured, damaged, diseased or aged articular cartilage or bone, using the acellular matrix implant implanted into a joint cartilage lesion in situ and a bone-inducing composition implanted...

20060083727 - Methods and compositions for the treatment of diseases characterized by calcification and/or plaque formation: The invention provides methods and compositions that include a nutraceutical supplement, antibiotic, and metal chelating agent that is administered to a patient to treat or prevent pathological calcification and or plaque formation as associated with Nanobacteria Calcifying Nano-Particles and/or diseases caused there-from, The method includes the administration of a therapeutically...

20060083732 - Hyaluronic acid in the enhancement of lens regeneration: The present invention addresses the treatment of ocular conditions by the enhancement of lens regeneration. This is accomplished by the administration of a high viscosity composition including a hyaluronic acid compound. Excess high viscosity composition may be removed by focal laser photophacoablation or through the use of a digestive compound...

20060083731 - Use of an enzyme for the manufacture of an agent for controlling bacterial infection: Xylanase or a cellulase for the manufacture of an agent for the treatment and/or prophylaxis of bacterial infection in an animal caused by Salmonella, Campylobacter or Clostridium perfringens. It is preferred that xylanase is used in combination with wheat to form an animal feed. Such a diet is particularly effective...

20060083734 - Composition and method for repairing nerve damage and enhancing functional recovery of nerve: The present invention relates to a fibrin glue composition for repairing a nerve damage, and/or enhancing the functional recovery of a damaged nerve which comprises an effective amount of nerve growth factor and/or nerve repair enhancer, fibrinogen, aprotinin and divalent calcium ions. The invention also relates to a method for...

20060083733 - High-concentration preparation of soluble thrombomodulin: In preparing a soluble thrombomodulin solution having a concentration of as high as 10 mg/mL or above, foam-inhibiting effect can be attained by any method selected from among (a) incorporation of a nonionic surfactant, benzyl alcohol or chlorobutanol, (b) application of silicone coating on the inner wall of the vessel...

20060083735 - Antigen-presenting complex-binding compositions and uses thereof: A composition-of-matter comprising an antibody or antibody fragment including an antigen-binding region capable of specifically binding an antigen-presenting portion of a complex composed of a human antigen-presenting molecule and an antigen derived from a pathogen is disclosed....

20060083736 - Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders: Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunosuppressive without conjugation to a therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment and prevention of CD70-expressing cancers and immunological...

20060083737 - Intracellular peptide delivery: Methods and kits for transporting heterologous compounds into cells, particularly mammalian cells, are disclosed. The method involves the pretreatment of the cell with a polycation, cationic polymer and/or cationic peptide before transportation of the heterologous compound into the cell. The methods are particularly applicable to the transport of peptides and...

20060083738 - Treatment of cancer by the use of anti fas antibody: The present invention provides a method of killing cancer cells and method of treatment of cancer comprising administration of a therapeutically effective amount of a) a specific binding member which binds to a cell death receptor or a nucleic acid encoding said binding member and (b) a chemotherapeutic agent. The...

20060083739 - Treating prostate cancer with anti-erbb2 antibodies: The present application discloses treatment of prostate cancer with anti-ErbB2 antibodies....

20060083740 - Manipulation of cytokine levels using cd83 gene products: The invention provides methods for modulating cytokine levels, GM-CSF levels and the immune system using CD83 nucleic acids, CD83 polypeptides, anti-CD83 antibodies and factors that influence CD83 activity or expression. The invention also provides mice having a mutant CD83 gene and mice having a transgenic CD83 gene, which are useful...

20060083741 - Treatment of respiratory syncytial virus (rsv) infection: The invention describes methods of treating and preventing respiratory syncytial virus (RSV) infection comprising administering a TNF inhibitor and an additional therapeutic agent. The invention also describes methods of treating and preventing respiratory syncytial virus (RSV) infection comprising administering an anti-TNF antibody and an anti-RSV antibody....

20060083744 - B7-h1 and methods of diagnosis, prognosis, and treatment of cancer: The invention features methods of diagnosis by assessing B7-H1 expression in a tissue from a subject that has, or is suspected of having, cancer, methods of treatment with agents that interfere with B7-H1-receptor interaction, methods of selecting candidate subjects likely to benefit from cancer immunotherapy, and methods of inhibiting expression...

20060083745 - Cancer treatment kits comprising therapeutic conjugates that bind to aminophospholipids: Disclosed is the surprising discovery that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are specific, accessible and stable markers of the luminal surface of tumor blood vessels. The present invention thus provides aminophospholipid-targeted diagnostic and therapeutic constructs for use in tumor intervention. Antibody-therapeutic agent conjugates and constructs that bind to aminophospholipids...

20060083743 - Method of cancer therapy by in situ production of f5 antibodies: The invention refers to the production of antibodies named F5 in a cancer carrier and the effect they exert on the development of guest's tumor. F5 may down regulate the proliferation and life of cancer cells regardless the histological nature of the malignancy and the stage of tumor growth. The...

20060083742 - Prenyl-electrostatic switch, and methods of use: The present invention relates to a method of identifying compounds as candidate drugs for treatment of cancer by providing a cell expressing a GTPase protein that is regulated by a prenyl-electrostatic switch, contacting the cell with compounds to be evaluated, and selecting compounds able to regulate charge at the prenyl-electrostatic...

20060083746 - Receptor for b. anthracis toxin: The present invention relates to mammalian anthrax toxin receptor polypeptides and polynucleotides encoding same as well as related polypeptides and polynucleotides, vectors containing the polynucleotides and polypeptides, host cells containing related polynucleotide molecules, and cells displaying no anthrax toxin receptor on an exterior surface of the cells-minus cell lines and...

20060083747 - Fc fusion: The present invention relates to a simple method for generating antibody-based structures suitable for in vivo use. In particular, the invention relates to a method for the generation of antibody-based structures suitable for in vivo use comprising the steps of: (a) selecting an antibody single variable domain having an epitope...

20060083748 - Calixarenes for use as excipient for an active substance: The invention relates to an active substance excipient system, wherein the excipients are selected from the group of calixarenes or resorcinarenes. Said macromolecular excipients serve for transport of the active substance to the location of action and to a dosage and time-defined release of the same there. Metabolism, kinetics and...

20060083749 - Compositions and methods for the therapy and diagnosis of breast cancer: Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides....

20060083750 - Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis: The invention provides a vaccine including an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, with an adjuvant in a pharmaceutically acceptable medium. The invention also provides a method of treating or preventing disseminated candidiasis. The method includes administering an immunogenic amount of a...

20060083751 - Therapeutic agents: A method for treating diabetes in a mammalian subject in need of same wherein the method comprises: administering to the mammalian subject an agent capable of modulating a ganglioside GM-1 (GM-1) associated activity in an amount effect to treat the disease; wherein the agent, when in vivo, has an effect...

20060083753 - Fusobacterium polypeptides and methods of use: The present invention provides isolated polypeptides isolatable from a Fusobacterium spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides....

20060083752 - Novel compounds: This invention relates to newly identified Staphylococcal polynucleotides, polypeptides encoded by such polynucleotides, the uses of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides and recombinant host cells transformed with the polynucleotides. This invention also relates to inhibiting the biosynthesis or action of such...

20060083754 - Pharmaceutical combinations comprising corticoids and immunosuppressants for treating corticoid- and/or calcineurin inhibitors-resistant diseases: The use of a combination of a corticoid and a compound of formula I for the preparation of a medicament for the treatment of a corticoid-resistant disease and/or a calcineurin inhibitor-resistant disease, e.g. where T cells are involved in the pathophysiology....

20060083756 - Circovirus sequences associated with piglet weight loss disease (pwd): The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a...

20060083755 - Vaccine for feline infectious peritonitis: FIP vaccines were provided that use an N protein with a specific structure, or a fragment thereof, as an antigen. Preferred antigens of this invention are N proteins derived from a specific type I virus strain (KU-2). Vaccines comprising such an N protein confer preventive effects against a wide range...

20060083757 - Method for treating cardiac muscle disorders: Methods for treating cardiac muscle disorders, such as cardiac arrhythmias, by administration of a neurotoxin to cardiac muscle are disclosed. Bradycardia can be alleviated for several months by a single intrapericardial or intracardiac injection or infusion of a botulinum toxin. Tachycardia can be alleviated by preganglionic sympathetic nervous system administration...

20060083758 - Treatment of premenstrual disorders: Methods for preventing or treating a premenstrual disorder by peripheral administration of a botulinum toxin. The botulinum toxin can be administered to or to the vicinity of a trigeminal sensory nerve, thereby preventing or treating one or more of the symptoms of a premenstrual disorder....

20060083759 - Stabilization of the profile of release of active substances from a formulation: The invention discloses a method of a physical pre-treatment of an active substance, which modifies technologically important physical properties of the active substance so as to enable the manufacture of a formulation having a more stable release profile of the active substance over the whole shelf life of the medicine...

20060083761 - Personal care compositions comprising visible beads, cationic polymer, and surfactant: Personal care compositions comprise visible beads, cationic polymer, and surfactant. The visible beads in the personal care compositions can be utilized to provide an aesthetically pleasing appearance to the product. The visible beads can also be utilized to encapsulate and deliver skin benefit agents to the skin or hair. The...

20060083760 - Preparation of oil-in-water emulsions stabilised with recombinant collagen-like material and related products: The invention provides oil-in-water emulsions comprising recombinant collagen-like polymer in an amount sufficient to act as stabiliser of the emulsion. The polymer is especially a polypeptide which is free of helix structure, has an isoelectric point at least 0.5 pH units removed from the pH of the oil-in-water emulsion. Furthermore,...

20060083762 - Uses of compositions comprising electrophilic monomers and micro-particles or nanoparticles: The present disclosure relates to methods for treating keratin materials, including keratin fibers such as the hair, of a composition comprising, in a cosmetically acceptable medium, at least one electrophilic monomer and microparticles or nanoparticles....

20060083764 - Aerosol-based insecticide compositions and methods of using the same: An aerosol-based insecticide composition comprising an active ingredient, such as deltamethrin, and a suitable carrier is disclosed as well as a method for its use. The insecticide composition may optionally contain one or more surfactants. Deltamethrin is preferably used as the active ingredient in the insecticide composition because of its...

20060083763 - Method and apparatus for insect repellant system: The present invention is directed to methods, apparatuses and compositions directed to producing a chemical or biological barrier to protect human or animal subjects from insect pests....

20060083766 - Anti-termite agent: Anti-termite agent which comprises lignin or modified compound thereof as the active ingredient....

20060083765 - Methods for using and manufacturing a pesticide: A pesticide made from an amorphous silicate material with strong hydrophilic properties. A method of controlling biological pests using a burned rice hull material comprises the steps of: distributing the burned rice hull material on or mixed into a pest environment. The material may be used in its pure form...

20060083767 - Surgical prosthesis having biodegradable and nonbiodegradable regions: A prosthesis for repairing a hernia includes an adhesion-resistant biodegradable region and an opposing tissue-ingrowth biodegradable region. When the prosthesis is implanted into the patient, the adhesion-resistant biodegradable region covers a fascial defect of the hernia, and the tissue-ingrowth biodegradable region is located above the adhesion-resistant biodegradable region while being...

20060083768 - Method of thickening a coating using a drug: A method for the provision of a coating on an implantable medical device results in a medical device having a bio-absorbable coating. The coating includes a bio-absorbable carrier component. In addition to the bio-absorbable carrier component, a dissolved therapeutic agent component can also be provided. The coated medical device is...

20060083771 - Block-shaped scaffold for tissue engineering and production method thereof: A block-shaped scaffold for a tissue engineering with improved shape stability and less volume change in water is produce by the steps of approximate-uniformly mixing the particle-shaped material having 100 to 2000 μm diameter with a solution, where a biodegradable polymer is dissolved with an organic solvent, freezing, drying it...

20060083772 - Coating compositions for bioactive agents: A coating composition and related method for use in applying a bioactive agent to a surface in a manner that will permit the bioactive agent to be released from the coating in vivo. The composition is particularly well suited for coating the surface of implantable medical device, such as a...

20060083770 - Medical devices and methods of preparation and use: An implantable device having a coating with an eluting membrane and a permeable membrane disposed on a surface of the device is provided. The eluting membrane is typically a polymeric material capable of being infused with a biologically active, therapeutic substance. The permeable membrane is typically a polymeric material having...

20060083769 - Method and apparatus for preparing bone: Formed compositions for application to a bone surface of a human or animal subject, comprising: a bone material; and a carrier comprising denatured demineralized bone, where the composition is formed into a shape suitable for administration to the bone. Methods are provided for making formed compositions for application to a...

20060083773 - Artificial corneal implant: A material that can be applied as implants designed to artificially replace or augment the cornea, such as an artificial cornea, corneal onlay, or corneal inlay (intrastromal lens) is provided. The artificial corneal implant has a double network hydrogel with a first network interpenetrated with a second network. The first...

20060083774 - Neurophilin ligands for treating ocular conditions: The use of neurophilin ligands for treating glaucoma and lowering IOP is disclosed....

20060083775 - Feeds containing hop acids and uses thereof as supplements in animal feeds: Disclosed are methods for administering hop acids to alter the microbial population of the gastrointestinal tract of animals and to inhibit the growth of pathogenic organisms in the gastrointestinal tracts of animals. Also disclosed are methods of increasing weight gain, feed efficiency, milk production in mammals, and egg and meat...

20060083776 - Preparations for topical application and methods of delivering an active agent to a substrate: A multi-layer dressing and controlled-release composition for topical application to a substrate include an emulsion and an active agent incorporated into the emulsion. The active agent includes a protein. A method of delivering the active agent to the substrate provides the emulsion and incorporates the active agent into the emulsion...

20060083777 - Treatment of acne: The invention relates to the use of one or more antimicrobial metals selected from silver, gold, platinum, and palladium but most preferably silver, preferably formed with atomic disorder, and preferably in a nanocrystalline form, for the treatment of a acne. The nanocrystalline antimicrobial metal of choice may be used in...

20060083778 - Controlled release compositions of estradiol metabolites: The present invention provides improved sustained release formulations of estradiol metabolites, including 2-hydroxyestradiol, 2-methoxyestradiol, 4-hydroxyestradiol and 4-methoxyestradiol, useful for therapeutic treatments. The invention also provides methods of producing sustained release forms of estradiol metabolites. The compositions of the present invention include microparticles, nanoparticles, patches, crystals, gels, rods, stints, pallets, discs,...

20060083779 - Diiodothyroacetic acid and method of use: The present invention relates to a method of administering an effective amount of a diiodothyroacetic acid in order to shift the proportion between lean body mass and adipose tissue in favor of lean body mass in human individuals....

20060083780 - Cationic lipids and methods of use: The present invention provides compositions comprising cationic lipids, liposomes and nucleic acid-lipid particles comprising the cationic lipids, and methods of using such compositions, liposomes, and nucleic acid-lipid particles....

20060083781 - Functionalized solid lipid nanoparticles and methods of making and using same: In one aspect, the invention relates to functionalized solid lipid nanoparticles comprising a neutral lipid and a first functionalized polymer comprising at least one ionic or ionizable moiety and methods for providing same. In a further aspect, the invention relates to tumor targeting therapeutic systems, multimodal diagnostic therapeutic systems, thermoresponsive...

20060083782 - Methods and compositions useful for administration of chemotherapeutic agents: In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of a pharmaceutically active agent, wherein the agent is associated with a polymeric biocompatible material....

20060083783 - Treating metabolic syndrome with fenofibrate: A method of treating metabolic syndrome in a human diagnosed with metabolic syndrome by administering a therapeutically effective amount of fenofibrate over a treatment period. The results can include identifying a human as not having clinical metabolic syndrome after treatment, as compared to having metabolic syndrome before treatment....

20060083784 - Amorphous pharmaceutical compositions: The present invention is directed to use of electrospinning, i.e. the process of making polymer nanofibers from either a solution or melt under electrical forces, to prepare stable, solid dispersions of amorphous drugs in polymer nanofibers. The present invention is also directed to the process of making solid dispersions of...

20060083785 - Large dose ribavirin formulations: The present invention is related to pharmaceutical dosage forms of ribavirin which are designed to increase patient compliance to a ribavirin therapy. Examples of such dosage forms include 400 mg to 600 mg tablets. These dosage forms are bioequivalent to multiple doses of tablets containing small amounts of ribavirin....

20060083786 - Taste masking pharmaceutical composition containing levocetirizine: A solid oral dosage composition is provided comprising a prophilactically or therapeutically effective amount of an active pharmaceutical ingredient comprising levocetirizine or a pharmaceutically acceptable salt thereof, the solid oral dosage composition having a coating thereon capable of providing taste masking of the levocetirizine or pharmaceutically acceptable salt thereof....

20060083787 - Method of treating mammalian joint maladies by biological fluid transplantation: Disclosed is a product and method for transplanting biological fluids into a host animal (including humans) that have been collected from donor animals. These biological fluids have been purified and processed so that they are a cellular, sterile, pathogen free, and a form that can be stored for considerable periods...

20060083789 - Process and system for producing nuclear spin polarized xenon gas: The present invention provides producing method and producing apparatus in which polarized xenon gas of high concentration is obtained without being frozen, and polarized xenon gas can be produced continuously. A glass cell having solid rubidium and solid xenon filled in vacuum is heated to be gas xenon and gas-liquid...

20060083788 - Water containing active hydrogen and process for producing the same: Provided are novel water containing active hydrogen wherein the content of active hydrogen is high and a process wherein such active hydrogen-containing water is produced simply at high efficiency from an inexpensive material without needing complex apparatus or special treating agents. The water containing active hydrogen of the present invention...

20060083790 - Combination of an ibat inhibitor and a metal salt for the treatment of diarrhoea: A combination comprising an IBAT inhibitor, or a pharmaceutically acceptable salt, solvate of such a salt or a prodrug thereof, and a metal salt, wherein the metal salt is formulated to release in the terminal ileum, caecum and/or the colon, is described. Compositions containing this combination and uses of the...

20060083791 - Rare earth metal compounds methods of making, and methods of using the same: Rare earth metal compounds, particularly lanthanum, cerium, and yttrium, are formed as porous particles and are effective in binding metals, metal ions, and phosphate. A method of making the particles and a method of using the particles is disclosed. The particles may be used in the gastrointestinal tract or the...

20060083792 - Therapeutic treatments using the direct application of antimicrobial metal compositions: Therapeutic treatments using the direct application of selected structures of antimicrobial metals in free-standing powder form, solution form and/or suspension form in therapeutically effective amounts. The selected structures of antimicrobial metals serve as an antimicrobial agent, an anti-inflammatory agent, an immuno modulator agent, an enzyme modulator agent, and/or an anti-tumor...

20060083793 - Nutritional composition for promoting muscle performance and acting as hydrogen (h+) blocker: A nutritional composition that includes creatinol, e.g., creatinol O-phosphate, wherein the nutritional composition includes a timed release delivery system. The timed release delivery system may include one of quick release, slow release and controlled release delivery system. Ingestion of the nutritional composition provides a method for, e.g., promoting muscle performance...

20060083795 - Meal replacement products having appetite suppressing qualities: A meal replacement is provided herein. According to one exemplary embodiment, the meal replacement includes a meal replacement base, and an appetite suppressant including a succulent plant extract. According to one exemplary embodiment, the succulent plant extract is selected from the group consisting of Trichocaulon piliferum, Trichocaulon officinale, Hoodia gordonii,...

20060083794 - Use of an extract from the plant argania spinosa: A method and preparation which uses Argania spinosa is provided for treating acne, seborrhoea, unwanted hair, and having anti-5-α-reductase activity. The useful compositions contain from 0.01 to 25% by weight, based on a dry weight, of an extract of Argania spinosa....

20060083796 - Orally administrable composition for improving hair and coat quality: The present invention relates to an orally administrable composition for improving hair or coat quality, which comprises as an active ingredient an effective amount of a molecule that stimulates energy metabolism of the cell or an antioxidant or combinatory admixtures thereof, in an orally acceptable carrier....

20060083797 - Alcohol-fermented food or pharmaceutical composition for prevention of obesity and process for preparation thereof: The present invention relates to an extract of mixed herb medicine, and a pharmaceutical composition for the prevention and treatment of obesity containing the extract as an effective ingredient or health food containing the same, more precisely, an extract of mixed herb medicine extracted from the mixture of cassia seeds...

20060083798 - Composition of natural herb extract for treating cardiovascular disease and its method of preparation thereof: A composition of natural herb extract for treating cardiovascular disease or vascular disorder and its method of preparation and separation, and particularly to a composition prepared from natural herb extract comprising constituents of Danshensu, Tanshinone IIA, matrine, oxymatrine and puerarin for lowering the risk factors of heart disease or treating...

20060083799 - Anti-hypersensitive inflammation and anti-allergy activities of zingiber zerumbet (l.) smith: The present invention provides for a method of preparing a nutraceutical formulation comprising the step of solvent extraction from the root of Zingiber zerumbet Sm, and the use of this formulation to regulate the immune system, and more specifically to prevent or to treat an allergic disorder....

20060083800 - Composition for the treatment of malaria: A composition for use in treating malaria includes: 4%-38% fever nut by weight; 24%-89% kutaki by weight; 3%-28% five-leaved chaste tree by weight; and 3%-26% karchi by weight....

20060083801 - Method of disinfecting a building air supply: According to the invention there is provided a method of reducing microbial levels in the interior of a building, including vaporizing an anti-microbial essential oil to produce vaporized anti-microbial essential oil, entraining the vaporized anti-microbial essential oil in an air stream, and directing the air stream into the air ducts...

20060078493 - Methods and apparatus for localized administration of inhibitory moieties to a patient: Methods and devices are provided for the localized administration to a patient of moieties effective for inhibiting unwanted cellular growth, including restenosis of an artery treated with a stent implant for blockage of blood flow by an atherosclerotic lesion. After implantation of a medical device capable of moiety-binding, moieties effective...

20060078495 - Stereoisomers of fatty acid analogs for diagnostic imaging: The present invention provides novel imaging agents for clinical diagnosis of injuries and diseases, in the form of a radionuclide in spatial proximity to a substantially pure stereoisomer of a fatty acid analog. The invention also provides methods for using the novel imaging agents, and kits containing one or more...

20060078494 - Use of inhibitors of 24-hydroxylase in the treatment of cancer: The present invention relates to a method of treating cancer in a subject. The method comprises administering to a subject suffering from cancer a therapeutically effective amount of a 24-hydroxylase inhibitor in combination with a second amount of a suitable cancer therapeutic. The 24-hydroxylase inhibitor can be coadministered with a...

20060078496 - Method of drug delivery to interstitial regions of the myocardium: A method of treating the heart and other body tissues by injecting a compound comprised of microsphere encapsulated macromolecule therapeutic agents into the myocardium, such that the microsphere size inhibits capillary transport of the compound but may permit lymphatic transport of the compound, and the compound releases therapeutic agents upon...

20060078497 - Health management and monitoring with and without weight loss: Health management and monitoring predicated on an intermittent calorie restricted health management paradigm is provided. In an illustrative implementation, an intermittent calorie restricted health management program is provided to a participating health management subject so improve the health state of the participating subject (e.g., impact disease states in the health...

20060078498 - Methods for the identification of novel ligands for the g protein-coupled receptor (gpcr) 192: The present invention relates to methods for the identification and characterization of polypeptides with ligand activity for the G protein coupled receptor (GPCR) 192. The invention encompasses the use of the ligands in combination with the receptor for the development of assays/kits for the identification of molecules that affect the...

20060078499 - Use of hedgehog agonist to treat depression: This invention provides methods for determining whether an agent, known to upregulate the sonic hedgehog pathway, increases brain progenitor cell division in a subject. Furthermore, this invention provides methods for treating anxiety, depression, a cognitive disorder or a neuro-degenerative disorder or inhibiting the onset of anxiety, depression or a cognitive...

20060078500 - Compositions for detecting hyaluronidase activity in situ and methods of utilizing same: A composition-of-matter is provided. The composition-of-matter comprising a chelator moiety-hyaluronan complex bound to a solid support. Also provided are methods of in-situ assessing hyaluronidase activity using such compositions....

20060078502 - Charge neutral complexes of paramagnetic metals as intracellular magnetic resonance imaging contrast agents: A contrast agent for magnetic resonance imaging comprising a complex of a paramagnetic cation, preferably Gd+3, Dy+3, and Fe+3 with three equivalents of a charge neutralizing chelator that provides a lipid soluble complex of the paramagnetic cation is described. The complex is retained intracellularly when introduced into a mammalian cell....

20060078503 - 1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them: c

20060078501 - High frequency ultrasound imaging using contrast agents: Provided herein are compositions comprising a microbubble contrast agent, wherein at least 20% by volume of the microbubbles in the contrast agent has a size of less than 1 micron, wherein the contrast agent produces non-linear scattering when contacted by ultrasound at a frequency above 20 MHz. Provided herein are...

20060078505 - Methods and kits for delivering drugs by nebulisation: Methods for administering drugs by nebulisation, together with kits for carrying out the methods, and including components for the production of such kits and unit dose vials....

20060078506 - Methods, systems and devices for noninvasive pulmonary delivery: The invention is directed to noninvasive methods, systems and devices for pulmonary delivery of aerosolized active agents and methods of treating respiratory dysfunction....

20060078504 - Sustanined-release pharmaceutical composition for lung administration: The present invention provides a sustained-release pharmaceutical composition containing a pharmacologically active substance, the pharmaceutical composition being able to control the pulmonary absorption of the pharmacologically active substance and produce prolonged pharmacological effects when administered via the pulmonary route. The invention provides a pharmaceutical composition containing carrageenan and a pharmacologically...

20060078507 - Aerosol device containing a composition comprising at least one propellant, at least one acrylic associative polymer, and at least one fixative polymer: Disclosed herein is a composition packaged in an aerosol device, containing: at least one propellant; and a hairstyling composition comprising (i) at least one non-polyurethane anionic or non-ionic fixative polymer and (ii) at least one anionic acrylic associative polymer; wherein the at least one propellant is present in an amount...

20060078508 - Effervescent pressed gum tablet compositions: The present invention includes pressed gum tablets that effervesce when chewed. The effervescent pressed gum tablets include a particulate chewing gum base, a tableting powder and an effervescent system. The effervescent system may include a base and an edible acid. The effervescent system further may include active components, such as...

20060078509 - Effervescent pressed gum tablet compositions: The present invention includes pressed gum tablets that effervesce when chewed. The effervescent pressed gum tablets include a particulate chewing gum base, a tableting powder and an effervescent system. The effervescent system may include a base and an edible acid. The effervescent system further may include active components, such as...

20060078510 - Dental coating kit: The invention provides a dental coating kit with high adhesiveness to teeth that contains a primer composition including an acidic group-containing polymeric monomer (a), water (b) and a water-soluble solvent (c) and a surface smoothing composition including a polyfunctional polymeric monomer (f), a volatile solvent (g) and a photopolymerization initiator...

20060078512 - Liquids to gel: A method of forming a gel by combining two or more liquid components at the time of use. An excellent application of such a system would be for tooth whitening, but this system can also be used for other purposes such as hair care, printing inks, cleaning products, and the...

20060078511 - Treatment of bruxism: A composition and its use for local percutaneous delivery of a drug, in particular a muscle relaxant, more particularly cyclobenzaprine present in an amount of about 1 to about 10% by weight of the composition in an organogel cream are disclosed. The composition is applied directly to the skin over...

20060078513 - Oral care system: This invention discloses a multi-purpose oral hygiene system for the mouth and teeth with a liquid tooth-whitening product composed of natural ingredients that can be swallowed mixed with a liquid breath freshener in a container to hold and deliver the tooth-whitening product and breath freshener to the mouth and teeth....

20060078516 - Sunless tanning system: A sunless tanning system comprising a mitt applicator and novel packaging therefor. The exterior of the mitt is impregnated with sunless tanning composition and the interior of the mitt is constructed to prevent the penetration of sunless tanning composition. The packaging is configured so that when it is opened there...

20060078514 - Sunscreen compositions: A sunscreen composition which includes at least one UV-B active ingredient therein, optionally with a UV-A active, and a phenylethyl or benzyl ester in an amount sufficient to boost the SPF rating of the UV-B active therein....

20060078515 - Sunscreen wipes: The invention relates to a product comprising a wet wipe and a sunscreen (colored or white) emulsion. The sunscreen emulsion is impregnated into the wet wipe resulting in the even spread of the colored sunscreen with more convenience, and significantly reducing the mess and waste normally resulting from the application...

20060078518 - Cosmetic compositions containing fluorescent colorants for natural skin appearance: Cosmetic or personal care compositions which comprise at least one fluorescent colorant other than white and at least one non-fluorescent colorant, are useful in preparing colored cosmetic or personal care preparations providing an enhanced skin appearance....

20060078517 - Cosmetic dye composition with a lightening effect for human keratin materials, comprising at least one fluorescent dye and at least one aminosilicone, and process of dyeing: The present disclosure relates to a cosmetic composition comprising at least one fluorescent dye and at least one aminosilicone; processes using this cosmetic composition and a kit comprising at least one composition comprising at least one fluorescent dye and at least one aminosilicone, which can be used to dye with...

20060078519 - Compositions comprising particles of at least one polymer dispersed in a fatty phase: The present disclosure relates to cosmetic compositions comprising particles of at least one polymer dispersed in a fatty phase, wherein the fatty phase is free of volatile oil or comprises less than 50% by weight of volatile oil, relative to the weight of the fatty phase. The polymer may be...

20060078523 - Composition comprising at least one electrophilic monomer and at least one acid in a cosmetically acceptable anhydrous medium, and use thereof for cosmetic treatment of the hair: Disclosed herein is a cosmetic composition comprising at least one electrophilic monomer and at least one non-reducing organic acid containing from 1 to 12 carbon atoms in a cosmetically acceptable anhydrous medium, and its use for the cosmetic treatment of the hair. Also disclosed herein is a method of cosmetic...

20060078522 - Composition for treating keratin materials comprising at least one electrophilic monomer and at least one salt: Disclosed herein is a cosmetic composition for treating keratin materials, for example, keratin fibers such as the hair, comprising, in a cosmetically acceptable medium, at least one electrophilic monomer and at least one organic or mineral salt. Also disclosed is a method for cosmetically treating keratin materials comprising applying the...

20060078521 - Cosmetic composition based on nonionic guar gum and on non-crosslinked anionic polymer: The present invention relates to non-washing cosmetic compositions containing, in a cosmetically acceptable medium, at least one nonionic guar gum and at least one non-crosslinked anionic polymer. The invention also relates to a process for the cosmetic treatment of keratin substances, such as the hair or the eyelashes, characterized in...

20060078524 - Multi phase personal care composition comprising a conditioning phase and an oil continuous benefit phase: Multi-phase personal care compositions comprising a fatty compound-cationic surfactant conditioning phase, and at least one benefit phase selected from the group consisting of high internal phase water-in-oil emulsions, hydrophobic gel networks, hydrophobic oil phases, and a silicone or silicone gel. These products are intended to provide a multi-phase personal care...

20060078525 - Microemulsion: A microemulsion composition containing the following ingredients (A) through (F): (A) a hydrophilic nonionic surfactant having as a hydrophilic group a residue of a sugar, reducing sugar or polyglycerin having a hydrogen atom of at least one hydroxyl group thereof removed; (B) a hydrophilic nonionic surfactant having a polyoxyethylene chain...

20060078526 - Thickenable compositions: A composition comprises water, a first anionic polymer and a second anionic polymer. The first anionic polymer may be xanthan. The second anionic polymer may be selected from an alginate, a carboxymethylcellulose, an acrylate polymer, a carrageenan and a pectin. The composition is such that diluting it with water increases...

20060078528 - Hair conditioning composition comprising tight lamellar gel matrix: Disclosed is a hair conditioning composition comprising: a cationic surfactant; a high melting point fatty compound; and an aqueous carrier; wherein the cationic surfactant, the high melting point fatty compound, and the aqueous carrier form a lamellar gel matrix; wherein the d-spacing of the lamellar layers is in the range...

20060078527 - Multi phase personal care composition comprising a conditioning phase and a water continuous benefit phase: Multi-phase personal care compositions comprising a fatty compound-cationic surfactant conditioning phase, and at least one benefit phase selected from the group consisting of a second fatty compound-cationic surfactant, a high viscosity aqueous phase, and high internal phase emulsions (HIPEs). These products are intended to provide a multi-phase personal care composition...

20060078529 - Hair conditioning composition comprising alkyl diquaternized ammonium salt cationic surfactant: Disclosed is a hair conditioning composition comprising an alkyl diquaternized ammonium salt cationic surfactant, a high melting point fatty compound, and an aqueous carrier. The composition of the present invention can provide improved conditioning benefits such as smoothness, softness, and ease of combing for both wet hair and dry hair....

20060078520 - Easily removable waterproof cosmetic care and/or makeup composition comprising at least one latex or pseudolatex: The present invention relates to a composition for making up and/or caring for keratin materials, the said composition having an aqueous continuous phase and comprising at least one aqueous dispersion of particles of a polymer, at least one polyelectrolyte and at least one surfactant with an HLB of greater than...

20060078530 - Using high-density grapes to rejuvenate human skin: The present invention provides a method for rejuvenating the skin by applying a chemical system that stimulates the skin to repair and build itself naturally at the same time the chemical system provides protection for the skin. More specifically, the stimulation of the skin is performed through the use of...

20060078533 - Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer: This invention relates to a method for prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, type 2 diabetes, dementia and some forms of arthritis and cancer in a subject comprising administering to said subject, separately, sequentially or simultaneously a therapeutically effective...

20060078532 - Method of prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and alzheimer's disease: This invention relates to a method for prevention and treatment of Atherosclerosis, Peripheral Vascular Disease, Coronary Artery Disease, and age-related disorders including Osteoporosis, Arthritis, Type II Diabetes, Dementia and Alzheimer's disease in a subject comprising administering to said subject a therapeutically effective dosage of each component or combination of statins,...

20060078531 - Method of prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and alzheimer's disease: This invention relates to a method for prevention and treatment of Atherosclerosis, Peripheral Vascular Disease, Coronary Artery Disease, and age-related disorders including Osteoporosis, Arthritis, Type II Diabetes, Dementia and Alzheimer's disease in a subject comprising administering to said subject a therapeutically effective dosage of each component or combination of statins,...

20060078534 - Toxin binding compositions: Methods and compositions for the treatment of toxin-mediated diseases are provided herein. One aspect of the invention is oligosaccharide-based therapeutics that interact with toxins and methods of uses thereof. In one embodiment the oligosaccharide-based therapeutics of the invention comprise polymeric particles with attached oligosaccharide binding moieties. The compositions of the...

20060078535 - Anticancer compounds and methods: The testing of tumor cells, including human tumors capable of metastases, in assays employing fibronectin-depleted substrates is described. Ex vivo induction of cells, including biopsied human cells, is performed with invasion-inducing agents. Additionally, anti-cancer chemotherapeutics are described. Specifically, chemotherapeutic agents which have anti-metastatic and anti-growth properties are described including non-peptide...

20060078536 - Polysaccharide-based polymer tissue adhesive for medical use: Tissue adhesives formed by reacting an oxidized polysaccharide with a water-dispersible multi-arm polyether amine, wherein at least three of the arms are terminated by primary amine groups, are disclosed. The use of the tissue adhesives for medical and veterinary applications such as topical wound closure; and surgical procedures, such as...

20060078537 - Mono-and dual chemokine/cytokine constructs: The present invention relates to a chemokine construct comprising a scFV anti-CD4 and a RANTES chemokine or a functional fragment thereof, whereby said chemokine construct has the structural domain form of (a) RANTES-linker-(VH) anti-CD4-linker-(VL) anti-CD4; or (b) (VL) anti-CD4-linker-(VH) anti-CD4-linker-RANTES, or (c) (VH) anti-CD4-linker-(VL) anti-CD4-linker-RANTES, whereby in the alternatives (b)...

20060078538 - Thermal surgical procedures and compositions: Methods, compositions, and systems useful to enhance a thermal surgical procedure are described. Compositions include at least one compound effective to induce an inflammatory response in biological material identified to undergo a thermal surgical procedure. Methods and systems include providing compositions of the invention to biological materials and treating biological...

20060078539 - Remedies for tumor in hematopoietic organs: An inducing agent or enhancing agent, for the expression of HM1.24 antigen in hematopoietic tumor cells, comprising interferon α, interferon γ, or the IRF-2 protein as an active ingredient, as well as an anti-tumor agent for hematopoietic tumors which comprises a combination of said inducing agent or enhancing agent and...

20060078540 - Dendritic cell nodes: The present invention features dendritic cell nodes that can be used to vaccinate subjects against pathogens and to modulate a subject's immune system to treat or prevent various diseases and conditions....

20060078541 - Method and formula for stem cells' stimulation, targeting release, trafficking and homing: The present invention relates to the fields of pharmacology, regenerative medicine, electro-physiology, and stem cell therapy. In a method aspect, a method of stimulating stem cell release in a mammal is provided. The method includes the step of administering a composition to the mammal, and wherein the composition comprises from...

20060078542 - Gel-based delivery of recombinant adeno-associated virus vectors: Disclosed are water-soluble gel-based compositions for the delivery of recombinant adeno-associated virus (rAAV) vectors that express nucleic acid segments encoding therapeutic constructs including peptides, polypeptides, ribozymes, and catalytic RNA molecules, to selected cells and tissues of vertebrate animals. Also disclosed are gel-based rAAV compositions are useful in the treatment of...

20060078545 - Neural progenitor cell populations: This invention provides populations of neural progenitor cells, differentiated neurons, glial cells, and astrocytes. The populations are obtained by culturing stem cell populations (such as embryonic stem cells) in a cocktail of growth conditions that initiates differentiation, and establishes the neural progenitor population. The progenitors can be further differentiated in...

20060078543 - Neural progenitor cells derived from embryonic stem cells: The present invention relates to undifferentiated human embryonic stem cells, methods of cultivation and propagation and production of differentiated cells. In particular it relates to the production of human ES cells capable of yielding somatic differentiated cells in vitro, as well as committed progenitor cells such as neural progenitor cells...

20060078544 - Novel cancer-associated antigens and methods of their identification and use: The present invention provides novel, isolated, tumor-associated antigens, and methods for identifying such antigens in a biological sample, and of screening for the presence of such an antigen in a biological specimen, wherein the tumor antigen identified reacts with serum from a subject treated with a vaccine comprising a cytokine...

20060078548 - Microorganisms having intestinal cell surface glycosylation modulating action: The invention concerns micro-organism strains, in particular of lactic acid bacteria, having a glycosylation modulating effect of intestinal cell surface. The invention also concerns a method for selecting micro-organism strains, in particular of lactic acid bacteria, which consists in measuring the average fluorescence intensity variation of HT29-MTX cells incubated in...

20060078547 - Probiotic lactobacillus salivarius strains: A Lactobacillus salivarius strain, AH102, AH103, AH105, AH109 or AH110 or mutants or variants thereof are useful in the prophylaxis and/or treatment of inflammatory activity especially undesirable gastrointestinal inflammatory activity, such as inflammatory bowel disease or irritable bowel syndrome....

20060078546 - Use of lactic acid bacteria to reduce sick time: A method of decreasing sick time, and thus sick-leave, in which selected strains of lactic acid bacteria are administered....

20060078549 - Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as huntington's disease, by using coenzyme q10: A method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as Huntington's disease, includes administering a formulation including mitochondrial coenzyme Q10 in a subject in need thereof. The formulation includes Hydro-Q Sorb®, which is a complex of coenzyme Q10 and cyclodextrin....

20060078551 - Novel therapeutic and prophylactic agents and methods of using the same: A phospholipase A2 inhibitor protein designated “Phospholipase Inhibitor from Python” (PIP)—formerly designated “Python Antitoxic Factor” (PAF)—is given by SEQ ID NO:2. The partial amino acid sequence for PIP was initially determined from the native protein purified from the blood serum of a non-venomous snake, Python reticulatus. The complete PIP polynucleotide...

20060078550 - Porcine fgl2: The present invention relates to porcine fgl2 gene and protein and methods of modulating the gene and protein. The methods are useful in preventing thrombosis associated with the xenotransplantation of porcine organs or tissues....

20060078553 - Diverse multi-unit complexes including a trna synthetase fragment: The present invention relates to compositions comprising a Met-tRNA synthetase fragment and a non-Met-tRNA synthetase fragment as well as uses thereof. In some embodiments, the Met-tRNA synthetase fragment is more than 50% of the composition. In other embodiments, the non-Met-tRNA synthetase fragment is more than 50% of the composition. Such...

20060078552 - Hybrid and single chain meganucleases and use thereof: This patent application relates to hybrid and/or single-chain rare-cutting endonucleases, called meganucleases, which recognized and cleave a specific nucleotide sequence, to polynucleotide sequences encoding for said rare-cutting endonucleases, to a vector comprising one of said polynucleotide sequences, to a cell or animal non-human comprising one of said polynucleotide sequences or...

20060078554 - Angiotensin peptide-carrier conjugates and uses thereof: The present invention provides conjugates of peptide derivatives of the mammalian peptide hormones angiotensinogen, angiotensin I and angiotensin II, presented in a repetitive scaffold by coupling the peptide derivatives to a carrier, particularly a virus-like particle (VLP). The invention also provides methods of producing such conjugates, and immunotherapeutic uses of...

20060078555 - Intraventricular hemorrhage thrombolysis: The invention provides methods of treating intraventricular hemorrhage using thrombolytic agents....

20060078556 - Antibodies and epitopes specific to trna synthetase fragments: The present invention relates to antibodies that specifically bind to an epitome of a tRNA synthetase fragment. Such epitopes are preferably N-terminus epitopes or bind to the N-terminus of a tRNA synthetase fragment. The invention also relates to epitope peptides useful in generating the above antibodies....

20060078557 - Methods and compositions for promoting immunopotentiation: This invention discloses immunopotentiating agents which stimulate an immune response. These agents are categorized into single agents that act directly, adjuvants added concurrently with the agents, or heteroconjugates. Heteroconjugate agents elicit or enhance a cellular or humoral immune response which may be specific for an epitope contained within an amino...

20060078558 - Diagnosis, prognosis and treatment of pulmonary diseases: The present invention provides methods to protect a subject from a respiratory disorder involving an airway obstructive disease such as asthma or chronic obstructive pulmonary disease. Provided are methods to protect a subject from an airway obstructive disease using gene therapy. Methods are provided for supplying FoxA2 function to cells...

20060078559 - Ligand for g-protein coupled receptor fprl2 and uses thereof: The present invention relates to methods, reagents and kits for detecting of formyl peptide receptor like-2 (FPRL2) polypeptide activity in a sample and identifying agents which modulate polypeptide activity. It further relates to antibodies raised against FPRL2. It further relates to substances for preventing, treating and/or alleviating diseases or disorders...

20060078560 - Method of inducing apoptosis and inhibiting cardiolipin synthesis: The present invention provides a method for inducing apoptosis within a cell by exposing the cell to an inhibitor of cardiolipin synthesis under conditions sufficient to induce apoptosis within the cell. The method can be used to investigate or treat disorders such as cancer, obesity, and cardiovascular disorders. The invention...

20060078561 - Polyclonal antibody libraries: The invention is directed to methods for the creation and use of libraries of proteins which comprise polyclonal antibodies to a common antigen or group of antigens, receptor proteins with related variable regions, or other immune related proteins with variable regions. These polyclonal antibody libraries can be used to treat...

20060078564 - Family of immunoregulators designated leukocyte immunoglobulin-like receptors (lir): A new family of immunoreceptor molecules of the immunoglobulin superfamily, (LIR) polypeptides is described. Disclosed are sequences encoding LIR family members and their deduced amino acid sequences, polypeptides encoded by DNA that hybridize to oligonucleotide probes having defined sequences, processes for producing polypeptides of the LIR family, and antagonistic antibodies...

20060078562 - Rage fusion proteins and methods of use: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity...

20060078563 - Using heat shock proteins to increase immune response: The present invention provides for a method of using heat shock proteins (HSPs) to amplify the immune response initiated by a vaccine. HSPs can be introduced into a subject before, concurrently, or after the administration of a vaccine. The HSPs can also be used to activate antigen presenting cells which...

20060078566 - Antigen orf rv2430c and a method thereof: The present invention relates to a PPE family antigenic protein Rv2430c of SEQ ID No. 1; a set of three high antigenic index peptides of SEQ ID Nos. 2 to 4; an antigenic ORF Rv2430c of SEQ ID No. 5 and lastly a method of inducing immune response against Mycobacterium...

20060078565 - Nucleic acids and proteins from group b streptococcus: Protein antigens from Group B Streptococcus are described, together with nucleic acid sequences encoding them. Their use in vaccines and screening methods are described....

20060078567 - Method of preventing acute pulmonary cell injury: The present invention discloses a method of preventing acute pulmonary cell injury associated with ALI or ARDS and a method of inhibiting an inflammatory response in pulmonary cells by increasing levels of HSP70 protein....

20060078568 - Use of the residues from wine production: A cosmetic or pharmaceutical preparation comprising a winemaking residue is comprised of from about 1 to about 10% by weight of polyphenols and from about 25 to about 50% by weight of proteins, based on the dry residue weight. The press residues obtained in the flocculation of the fermented grape...

20060078569 - Method for recovery of photo-inhibited immunological activity: The present invention provides a novel method for recovery of photo-inhibited immunocompetence, which comprises administration of a specific active ingredient exhibiting physiological activity such as activity of activating cellular immunocompetence, which is obtained from a raw material that exists in a large amount in the nature and can easily be...

20060078570 - Use of asafetida extract as medicine for abstinence of drugs: The present invention relates to the use of asafetida extract in the preparation of medicine for abstinence of drugs. The present invention further relates to a method for abstinence of drugs, which comprises administering a therapeutically effective amount of asafetida extract to subjects. The asafetida extract according to the present...

20060078571 - Methods for treating inflammation pain: The present invention relates to methods for treating neurogenic inflammation pain. The methods include administering an effective amount of a composition which includes a botulinum toxin component and a substance P component to a patient, thereby treating the neurogenic inflammation pain....

20060078572 - M. haemolytica outer membrane protein p1pe as a vaccine or vaccine component against shipping fever: Vaccines and methods against M. haemolytica infections in cattle. The vaccine compositions include a recombinant outer membrane protein of M. haemolytica designated PlpE and/or subunits thereof, alone or in combination with other antigenic components, and a carrier or diluent. The methods involve administering an effective immunizing amount of the vaccines...

20060078575 - Low profile combination device for gastrostomy or jejunostomy applications having anti-granuloma formation characteristics: A removable anti-granuloma covering made from an anti-granuloma composition including at least one anti-granuloma agent, wherein the removable anti-granuloma covering is adapted to outfit a medical device for insertion in an artificial opening in a body of a being and wherein the removable covering is adapted to contact an area...

20060078573 - Methods of modifying crystal habit: The invention provides methods of modifying the crystal habit of a compound without altering the crystal structure of the compound through a controlled precipitation technique in the presence of a crystal growth inhibitor as well as the crystallized compounds formed by these methods. Using these methods, the crystal habit of...

20060078574 - Purified phospholipid-non-steroidal anti-inflammatory drug associated compositions and methods for preparing and using same: A new pharmaceutical composition is disclosed comprising a purified phospholipid-selective and/for nonselective non-steroidal, anti-inflammatory drug associated complex and methods for making and using same. A screening method for identifying compounds that form phospholipid associated complexes is also disclosed....

20060078578 - Cosmetic compositions with montmorillonite stabilizing agent: A stabilized film forming cosmetic composition comprising a stabilizing effective amount of dispersed non-quaternary montmorillonite mineral and a film forming effective amount of a film forming component, and a method for compatibilizing ingredients in long wearing or transfer resistant cosmetic compositions by formulating such compositions with a non-quaternary montmorillonite mineral....

20060078576 - Method for producing hydronycarboxylic acid esters: The invention relates to mixtures of mono-, di-, and tri-esters of hydroxycarboxylic acids and to a process for producing them. The hydroxycarboxylic acid is preferably citric acid. In the disclosed process, hydroxycarboxylic acids or salts thereof are reacted with a mixture of alcohols corresponding to general formulae (I) R1—OH and...

20060078581 - Oily gel composition: Oily gel compositions which contain at least one member of specific N-acyl-L-glutamic acid dialkylamides (component A), at least one member of polyhydric alcohol compounds (component B), and an oily substrate (component C), in which the ratio by weight of (component A)/(component B) is from 1/3 to 1/990, may be prepared...

20060078577 - Organo-gel formulations for therapeutic applications: A composition suitable for the local delivery of cosmetic and/or pharmaceutical agents into the skin containing at least two biocompatible organic solvents, a polar lipid, a surfactant, water, urea and a thickener wherein the organic solvents include an ester and a dihydric and/or polyhydric alcohol is provided. Also disclosed are...

20060078579 - Organo-gel formulations for therapeutic applications: A composition suitable for the local delivery of cosmetic and/or pharmaceutical agents into the skin containing at least two biocompatible organic solvents, a polar lipid, a surfactant, water, urea and a thickener wherein the organic solvents include an ester and a dihydric and/or polyhydric alcohol is provided. Also disclosed are...

20060078580 - Organo-gel formulations for therapeutic applications: A composition suitable for the local delivery of cosmetic and/or pharmaceutical agents into the skin containing at least two biocompatible organic solvents, a polar lipid, a surfactant, water, urea and a thickener wherein the organic solvents include an ester and a dihydric and/or polyhydric alcohol is provided. Also disclosed are...

20060078582 - Use of compositions for treating rosacea: Rosacea is treated with a composition comprising an antimicrobial and at least one of an anti-inflammatory and a non-retinoid inhibitor of at least one of NF-KB, AP-1, MMPs, adhesion molecules, TLRs, and CD14. The composition may further comprise a retinoid....

20060078583 - Device for delivering an anti-microbial composition: The present invention provides anti-microbial foam dispensing hand-sanitizer devices. The devices provide ease and convenience of use, require no water for use, and have improved residue reduction. Also provided are kits and methods of use....

20060078585 - Amitraz compositions: The present invention provides a stable composition which comprises a non-hydroxyl-group-containing solvent mixture comprising N,N-diethyl-m-toluamide and γ-hexalactone, optionally with dimethyl sulfoxide, eucalyptol and 1-methoxy-2-propyl acetate; and an effective amount of each of amitraz and at least one additional parasiticidal compound, such as R-28153. Said composition allows for high concentrations of...

20060078584 - Multi-functional oxidizing composition: A composition comprising a stable anhydrous mixture of an oxidizing agent and an active halogen agent wherein the oxidizing agent is potassium hydrogen peroxymonosulfate and the active halogen agent is an alkali metal salt of dichloro-s-triazinetrione, halogenated dimethylhydantoin, or mixtures thereof, and a method of treating water with such compositions...

20060078586 - Barrier layer: A barrier layer and corresponding method of making provide anti-inflammatory, non-inflammatory, and anti-adhesion functionality for a medical device implantable in a patient. The barrier layer can be combined with a medical device structure to provide anti-adhesion characteristics, in addition to improved healing, non-inflammatory, and anti-inflammatory response. The barrier layer is...

20060078588 - Biocompatible coatings for stents: A coating for a medical device, particularly for a stent, is described. The coating comprises a polymer and a biologically responsive compound. The coating can also contain a drug to provide enhanced therapeutic effect....

20060078587 - Hydrophilic coatings for medical implements: Compositions, methods, devices and kits utilizing water-based hydrophilic coating formulations on medical implements. The composition for applying a coating comprises a sulfonated polyester, water, and a surface active agent. Methods for coating a medical implement comprise providing an aqueous dispersion comprising sulfonated polyester and surface active agent, contacting the medical...

20060078589 - Device for treating oral wound gaps: A device for treating oral wounds that form a gap and hence too large to suture. The device is intended to fill the resulting wound gap and upon contact with bleeding tissues cause local hemostasis. The device will remain in and protect the wound gap during the healing process. The...

20060078590 - Resorbable ceramic compositions: Ceramic precursor compositions and chemically bonded ceramic (CBC) materials, especially Ca-based, and a composite biomaterial suitable for orthopaedic applications. The CBC-system includes a binding phase (chemical cement) and additional phases with specified chemistry imparting to the biomaterial the ability of initial strength followed by interaction with the body tissue including...

20060078591 - Systems and methods for augmenting tissue volume: A method of treating volume deficiency in cosmetic surgery and in urological stress incontinence is based upon the transplantation of one or more biologic collagen based tissues into the subcutaneous, deep dermal, or peri urethral space. In the preferred embodiment, mechanically morsellized dehydrated embryonic bovine matrix tissue is used, which...

20060078592 - Drug delivery systems: A method for making an ocular drug delivery device involves subjecting the device to a supercritical fluid to remove contaminants from the device. The supercritical fluid includes supercritical carbon dioxide. The contaminants include unreacted monomers or oligomers present in the polymeric material used to form the device....

20060078594 - Iron complex: This invention relates to certain iron complexes which comprise ferrous or ferric iron and mono-, bi, tri- or hexadentate ligands containing a five- or six-membered aromatic or heterocyclic ring for use in the treatment and/or prevention of nutritional disorders and compositions containing such iron complexes. The iron complexes enhance the...

20060078593 - Nutritional compostions comprising a soluble viscous fiber in a solid crisp matrix: Disclosed are nutritional compositions having a solid crisp matrix, or a flour derived from the solid crisp matrix, said matrix comprising (A) from about 10% to about 50% by weight of a soluble viscous fiber, preferably guar; (B) from about 10% to about 99% by weight of a carbohydrate other...

20060078596 - Treatment of muscle fatigue: The present invention involves the use of a compound that reduces the level of free fatty acids circulating in the plasma of a subject in the manufacture of a medicament for the treatment of prevention of muscle (particularly cardiac or skeletal muscle) impairment or fatigue....

20060078595 - Use of glutamate and/or a glutamate precursor for the preparation of a nutritional or pharmaceutical preparation for the treatment or prevention of hyperpermeability or undesired permeability of the intestinal wall: A method for treatment for deterioration of a mucosal barrier, an intestinal dysfunction or injury, suboptimal intestinal wall maturation of new-borns, undernutrition, suboptimal intestinal blood flow, allergy, sepsis, translocation of pathogenic bacteria through an intestinal wall, endotoxaemia, or viral diarrhoea, in which the method includes orally or enterally administering to...

20060078598 - Animal feed containing an encapsulated ingredient: An encapsulated ingredient is disclosed comprising an ingredient component and a coating component. The coating component includes a lipid and one or more hydrophobic, high melting point compounds. The coating component typically has a melting point of at least about 70° C....

20060078597 - Ascorbic acid salt suspensions and use thereof as antioxidants: Suspensions comprising A) at least one oxidation-sensitive substance selected from the group consisting of carotenoids, retinoids and unsaturated fatty acids and B) solid particles of one or more salts of ascorbic acid in a dispersant in which the salts of ascorbic acid are insoluble....

20060078599 - Pharmaceutical composition applicable to body tissue: The present invention provides a non-water soluble, film-forming composition which adheres to body tissue and forms a pharmaceutical carrier to provide localized delivery of an antifungal agent to a treatment site. The composition will typically include: (a) an alkyl cellulose; (b) a hydroxyalkyl cellulose; (c) a pharmaceutically acceptable polar protic...

20060078601 - Compositions and methods for delivering estradiol in transdermal drug delivery systems: A blend of at least two polymers in combination with a drug provides a pressure-sensitive adhesive composition for a transdermal drug delivery system in which the drug is delivered from the pressure-sensitive adhesive composition and through dermis when the pressure-sensitive adhesive composition is in contact with human skin....

20060078602 - Device for transdermal administration of drugs including acrylic polymers: A transdermal delivery system is provided where the drug delivery rates, onset and profiles of at least one active agent are controlled by selectively manipulating the monomeric make up of an acrylic-based polymer in the transdermal drug delivery system. The drug carrier composition may be comprised of (a) one or...

20060078603 - Transdermal delivery of drugs based on crystal size: A blend of at least two polymers in combination with a drug provides a pressure-sensitive adhesive composition for a transdermal drug delivery system in which the drug is delivered from the pressure-sensitive adhesive composition and through dermis when the pressure-sensitive adhesive composition is in contact with human skin. According to...

20060078604 - Transdermal drug delivery device including an occlusive backing: A transdermal drug delivery system for the topical application of one or more active agents contained in one or more polymeric and/or adhesive carrier layers, proximate to a non-drug containing polymeric backing layer which can control the delivery rate and profile of the transdermal drug delivery system by adjusting the...

20060078600 - Transdermal therapeutic system suitable for heat application for promoting the permeation of active substances, and the use thereof: The invention relates to a transdermal therapeutic system (TTS) comprising at least one pharmacological active substance, which is suitable for heating up to a temperature above skin temperature, thereby promoting the permeation rate of the active substance. The transdermal therapeutic system comprises at least one layer containing the active substance...

20060078607 - Liposome formulation of 6,9-bis[(2-aminoethyl)-amino]benzo[g]isoquinoline-5, 10-dione dimaleate: A liposome pharmaceutical formulation of the compound of 6,9-bis-[(2-aminoethyl)-amino]benzo[g]isoquinoline-5,10-dione dimaleate, the method for the preparation and the use thereof....

20060078605 - Pharmaceutical composition of small-sized liposomes and method of preparation: A pharmaceutical composition of small sized unilamellar liposomes for the supply active principles by injection, with an improved permanency in the blood flow, where the unilamellar membrane contains a mixture of saturated lipids encompassing at least one lysophospholipid in a quantity from about 0.5 mol % to about 6.0 mol...

20060078606 - Sustained-release liposomal anesthetic compositions: The invention provides a method for obtaining local anesthetics encapsulated in liposomes, such as multivesicular liposomes, with high encapsulation efficiency and slow release in vivo. When the encapsulated anesthetic is administered as a single intracutaneous dose, the duration of anesthesia and half-life of the drug at the local injection site...

20060078608 - Flavored gelatin capsule and method for producing said capsule: The present invention is directed to a flavored capsule suitable for encapsulating a dose and a method for making a flavored capsule. In one embodiment, a flavored capsule comprises a gelatin, water and a flavoring. The flavoring may be present in the flavored capsule in a concentration of between about...

20060078612 - Chewable enteric coated aspirin tablets: The invention relates to a tablet capable of being chewed or disintegrated in the oral cavity, which comprises an enteric coated aspirin active ingredient, and preferably a lightly compressed matrix comprising directly compressible carbohydrate(s) and at least one sweetener....

20060078613 - Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy: The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at...

20060078611 - Enteric coated aspirin granules comingled with binder: The invention relates to a tablet capable of being chewed or disintegrated in the oral cavity, which comprises an enteric coated granule comprising an intimate mixture of an aspirin active ingredient and at least one binder capable of preferentially absorbing ambient moisture....

20060078610 - Method for producing pharmaceuticals or food supplements comprising pigmented polymer coatings: The invention relates to a method for producing pharmaceuticals or parts thereof or food supplements or parts thereof, by coating substrates with a film-forming coating agent containing a pigment which is incompatible with the coating agent. The invention also relates to appliances for carrying out said method, especially a drum...

20060078609 - Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water soluble and respectively base: The invention provides a novel pharmaceutical composition comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base characterized in that the acid respectively base:drug compound ratio is at least 1:1 by weight....

20060078614 - Taste-masked pharmaceutical compositions: There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more taste-masked active pharmaceutical ingredient(s), rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients wherein the ODT disintegrates on contact with saliva in the buccal cavity in about 60 seconds forming a smooth,...

20060078615 - Bilayer tablet of telmisartan and simvastatin: A bilayer tablet comprises a first layer formulated for instant release of the angiotensin II receptor antagonist telmisartan from a dissolving tablet matrix and a second layer formulated for instant release of the HMG-CoA reductase inhibitor simvastatin from a disintegrating or eroding tablet matrix....

20060078617 - Pharmaceutical compositions for the treatment of cancer: This invention relates to novel pharmaceutical compositions comprising a solid dispersion of the compound of Formula I below, to processes for preparing these novel pharmaceutical compositions and to their use for treating hyper-proliferative disorders, such as cancer, either as a sole agent or in combination with other therapies. Formula I...

20060078616 - Thermoreversible pharmaceutical formulation for anti-microbial agents comprising poloxamer polymers and hydroxy fatty acid ester of polyethylene glycol: The present invention provides a pharmaceutical formulation having thermoreversible properties, comprising: a) an anti-microbial agent; b) a poloxamer mixture containing at least two poloxamer polymers; and c) a hydroxy fatty acid ester of polyethylene glycol, wherein the formulation is a solid at room temperature and is a liquid-gel at body...

20060078618 - Lipid particles and suspensions and uses thereof: The present invention relates to formulations and methods for the mucosal and parenteral administration of lipid particles an suspensions. The formulations of this invention are stable lipid particles useful for oral delivery of water-insoluble therapeutic agents, vaccines and diagnostics. The compositions of this invention promote the mucosal absorption of biologically...

20060078619 - Method for the preparatin of paclitaxel solid dispersion by using the supercritical fluid process and paclitaxel solid dispersion prepared thereby: The present invention relates to a method for the preparation of paclitaxel solid dispersion by using the supercritical fluid process and paclitaxel solid dispersion prepared thereby, the paclitaxel solid dispersion being highly homogeneous and showing an improved solubility, thereby being effectively used for the preparation of paclitaxel injection and oral...

20060078621 - Method of providing customized drug delivery systems: A novel method of correlating the disposition of a specific drug in an individual patient to a controlled and modulated delivery system for optimizing therapeutic response of orally ingested dosage forms is provided. Such a method broadly encompasses a first determination of an individual's metabolic rate in terms of absorption...

20060078624 - Microparticles and nanoparticles containing a lipopolymer: Microparticle and nanoparticles comprised of a polymer and of a lipid-polymer conjugate (lipopolymer) are described. The particles can include a therapeutic or diagnostic agent and/or a ligand attached to the lipopolymer. Compositions comprising the particles and methods of treatment using the particles are also described....

20060078620 - Oil composition based on peroxidised lipids, which can be used in the treatment of xerostomia: The invention relates to an oily pharmaceutical composition based on peroxidised lipids and on silica, characterised in that it contains, as essential constituents, peroxidised lipids which have a degree of peroxidation of between 5 and 600 milli-equivalents per kilogram, and silica which is dispersed within said peroxidised lipids at a...

20060078622 - Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent: This invention relates to microparticles and/or nanoparticles containing a delivery agent and/or an active agent. This invention also relates to pharmaceutical formulations and solid dosage forms, including controlled release solid dosage forms of active agent and a delivery agent....

20060078623 - Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent: This invention relates to microparticles and/or nanoparticles containing a delivery agent and/or an active agent. This invention also relates to pharmaceutical formulations and solid dosage forms, including controlled release solid dosage forms of active agent and a delivery agent....

20060078625 - Compositions including krill extracts and conjugated linoleic acid and methods of using same: Methods and compositions for the prevention, therapy and/or treatment of several disease states. The methods comprise the administration of a therapeutically effective amount of a composition including krill extract and conjugated linoleic acid. In addition, the present invention provides new and improved therapeutic compositions including krill extracts and conjugated linoleic...

20060078626 - Opthalmic and contact lens solutions with a peroxide source and a cationic polymeric preservative: An ophthalmic solution including 0.01 to 0.0001 percent by weight of a peroxide producing agent and 0.1 to 500 parts per million of a cationic, polymeric preservative....

20060078627 - Composition for treatment of obesity or generally aiding weight loss in pill, powder or liquid form, by appetite reduction and metabolism increase, comprising: l- phenylalanine, caffeine, and one or more of the group of all forms of 5-hydroxytryptophan an: A method of treating a human subject suffering from obesity or who simply desires to lose weight is disclosed, which comprises administering to the subject an effective amount of a compound which enhances serotonin, noradrenaline, and adrenaline activity. The formula is comprised of effective amounts of caffeine, L-phenylalanine, and one...

20060078628 - Wound treating agent: The invention relates to a wound treating agent for humans and/or animals which contains a zeolite-iodine inclusion compound, to the use of such wound treating agent for the preparation of wound-stilling materials, especially compresses, plasters and/or dressing material, and to such wound-stilling materials....

20060078629 - Nutritional compositions and use thereof: A nutrient composition or combination of compositions for the treatment or prophylaxis of infections, in particular HIV/AIDS, and for the enhancement of immunity, based on selenium in synergistic combinations with biologically absorbable sources of glutathione, alkalinity enhancing components, a source of sulphur, an anti-mutagenic compound and for oral use, gastrointestinal...

20060078630 - Method for the production of flavonoid-containing compositions and use thereof: The present invention relates to a method for the production of plant extracts having a standardized flavonoid content, in particular having a standardized luteolin content. Plant material of Reseda plants which has been pre-extracted with water is extracted with a solvent and then concentrated. The compositions thus obtained are suitable...

20060078631 - Methods for treating glioblastoma with herbal compositions: The inventive subject matter relates to methods for treating glioblastoma, comprising administration of a composition comprising therapeutically effective amounts of supercritical extracts of rosemary, turmeric, oregano and ginger; and therapeutically effective amounts of hydroalcoholic extracts of holy basil, ginger, turmeric, Scutellaria baicalensis, rosemary, green tea, huzhang, Chinese goldthread, and barberry....

20060078632 - Composition comprising bamboo extract and the compounds isolated therefrom showing treating and preventing activity for inflammatory and blood circulation disease: The present invention relates to a composition comprising a bamboo plant extract for the prevention and treatment of inflammatory or blood circulation disease. The extracts of bamboo plant has potent anti-inflammatory activity by inhibiting NO production and blood circulation-improving activity by inhibiting elastase activity and healing the wound of vascular...

20060078633 - Extract of cercis chinensis having anti-oxidant activity and anti-aging activity, and cosmetical composition containing the extract for anti-oxidation, skin-aging protection and wrinkle improvement: The present invention relates to extract of Cercis chinensis having anti-oxidant activity and antiaging activity containing compound of chemical formula 1 to chemical formula 20, and cosmetical composition for anti-oxidation, skin-aging protection and wrinkle improvement containing the extract as effective ingredient. The extract of present invention having protective effect on...

20060073095 - Methods for screening antibody-producing cells on heterogeneous antigen substrates: Methods and compounds are disclosed that relate to screening and selection of monoclonal antibodies specific for antigens in heterogeneous antigen mixtures. Antibody-secreting cells such as hybridomas are modified to make them capable of directly binding antigens by capturing their secreted antibody products onto their surface membranes in appropriate binding density...

20060073098 - Irrigating solution for neurosurgical procedures: Saline is harmful to neuronal tissue as an irrigating solution during neurosurgical procedures. An irrigating solution to replace the use of saline during surgical procedure is provided. The irrigating solution includes polypeptides, magnesium, insulin and ATP in artificial CSF....

20060073097 - Method and index for diagnosing insulin resistance: The invention provides a method for the determination on of insulin sensitivity, insulin resistance, and non-insulin dependent Diabetes mellitus based on oral glucose tolerance test data and lipid ratios from reference populations that define an insulin resistance index he invention also provides m for using the IR index to determine...

20060073099 - Treatment screening methods: The invention includes a method to identify a method to enhance survival of a subject that has been exposed to a biological insult such as an ionizing radiation dose of LD50/30 by treating the exposed subject with a test compound an optically comparing the results to that obtained using control...

20060073101 - Method for convection enhanced delivery of therapeutic agents: A method for monitoring and controlling convection enhanced delivery of a therapeutic agent to a target tissue is disclosed. A tracer that is detectable, for example, by magnetic resonance imaging (MRI) and/or by X-ray computed tomography (CT) is co-infulsed with the therapeutic agent and used to monitor the distribution of...

20060073100 - Detection and therapy of vulnerable plaque with fluorescent and/or radiolabeled compositions: The present invention relates to methods for selectively targeting Photodynamic Therapy (“PDT”) to inflammatory components of vulnerable plaques. As such, the present invention provides methods for the identification of vulnerable plaques, using fluorescent compositions, which include photosensitizer compoisitions, and/or radiolabeled compounds, as well as methods to treat vulnerable plaques by...

20060073102 - Abuse-resistant opioid solid dosage form: The present invention pertains to a solid dosage form comprising an analgesically effective amount of opioid analgesic and an opioid abuse-deterring amount of a nontoxic N-methyl-D-aspartate receptor antagonist contained in a carrier which isolates, or separates, the antagonist from the opioid analgesic. The nontoxic N-methyl-D-aspartate receptor antagonist is released and...

20060073104 - Apoe4 domain interaction inhibitors and methods of use thereof: The present invention provides compounds that inhibit apoE4 domain interaction; and compositions, including pharmaceutical compositions, comprising the compounds. The present invention provides methods of treating apoE4-related disorders. The methods generally involve administering to an individual in need thereof a therapeutically effective amount of an apoE4 domain interaction inhibitor....

20060073103 - Controlled dosage aerosols with lecithin as surface-active agent: A controlled dosage aerosol containing at least one medicinal agent, pressure-liquefied isobutane as the propellant, and lecithin as the surfactant....

20060073105 - Novel dry powder inhalation system for transpulmonary administration: The present invention provides a novel dry powder inhalation system suitable for transpulmonary administration. The dry powder inhalation system of the present invention characterized by using a combination of: (1) a vessel housing a freeze-dried composition prepared by freeze-drying a composition liquid containing ingredients in a non-dissolved form, and has:...

20060073106 - Novel stabilized cinnamic ester sunscreen compositions: The invention relates to a method of enhancing the photostability of an encapsulated cinnamate derivative in a topical sunscreen composition which comprises introducing into such sunscreen composition an effective amount of at least one additional non-encapsulated sunscreen....

20060073107 - Use of vitamin d3 (cholecalciferol) in sunscreens: Despite the widespread availability of highly-protective sunscreens, there is a worldwide epidemic of skin cancer. A possible reason for this is that sunscreens, while limiting damage to the DNA, may promote cancer growth by preventing vitamin D synthesis in the skin. To have biologic effects, Vitamin D must be converted...

20060073108 - Liquid stick antiperspirant: One embodiment of the invention described herein includes a method for improving stability of an antiperspirant. The method includes preparing a blend that comprises dibenzylidene sorbitol; adding an antiperspirant active to the blend, to make an antiperspirant blend; and adding one or more alkaline earth silicate salts to the antiperspirant...

20060073109 - Hair treatment compositions: The invention provides a hair treatment composition such as a shampoo or conditioner comprising a disaccharide and a di-acid....

20060073110 - High ds cationic polygalactomannan for skincare products: A skin care composition is provided with a) from about 1 to about 90 wt % of a surfactant, b) at least about 0.05 wt % of a cationic polymer wherein the cationic polymer has a mean average molecular weight (Mw) from about 2,000 to about 10,000,000 Dalton, and the...

20060073111 - Method for identifying shampoo-resistant hair-binding peptides and hair benefit agents therefrom: A method for identifying shampoo-resistant hair-binding peptides is described. The shampoo-resistant hair-binding peptides bind strongly to hair from a shampoo matrix and are stable therein. Peptide-based benefit agents, such as peptide-based hair conditioners and hair colorants, based on the shampoo-resistant hair binding peptides are described. The peptide-based hair conditioners and...

20060073112 - Method of preventing hydrogen sulfide odor generation in an aqueous medium: The present invention relates to a fast acting chemical treatment for preventing the generation of hydrogen sulfide odor by the microbial metabolic activities of sulfate reducing bacteria. Specifically, the invention relates to a method for preventing hydrogen sulfide odor generation in a sulfur species-containing aqueous medium, which includes adding to...

20060073113 - Polyalkylene glycol derivative and modified bio-related substance: e

20060073115 - Chimeric antagonist anth1: A recombinant chimeric antagonist formed by a 60 amino acid fragment of the N-terminal region of human interleukin 2 (IL-2) fused to the N-terminal of the extracellular region of the alpha subunit of the gamma IFN (IFN γ) receptor. In vitro this protein has a T cell growth stimulating activity,...

20060073114 - Compounds and methods to inhibit or augment an inflammatory response: Isolated and purified chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs, are provided....

20060073116 - Identification and use of high efficacy vaccine antigens which modulate antigen presenting cells: The present invention relates to the identification and use of high efficacy vaccine antigens which modulate antigen presenting cells....

20060073117 - Methods and compositions for controlling hair follicle stem cell fate: The present invention relates to mutant hair follicle stem cells possessing an inactive Bmpr1a receptor, wherein such mutant hair follicle stem cells proliferate and undergo self-renewal. Additionally, the present invention relates to compositions and methods for induction of hair follicle stem cell proliferation in vivo and in vitro. The present...

20060073118 - Methods of activating nkt cells: Provided are methods of activating an NKT cell which include a step of contacting the NKT cell with a sufficient amount of isoglobotrihexosylceramide (iGb3) to induce secretion of a cytokine from the NKT cell, stimulate proliferation of the NKT cell or upregulate expression of a cell surface marker on the...

20060073120 - Ikkalpha and ikkbeta specific inhibitors: A method for modulating NF-κB dependent gene transcription in a cell comprised of modulating IKKα and IKKβ protein and protein activity in the cell. The present invention also provides siRNA compositions and methods thereof for modulating NF-κB dependent gene transcription....

20060073119 - Methods for treating neurodegenerative disorders: Vectors and methods are provided for treatment of neurodegenerative disorders by administration of anti-inflammatory cytokines, such as IL-10. Anti-inflammatory cytokines can be administered as a protein or by gene therapy, using plasmid delivery or a viral vector such as adeno-associated virus (AAV). Diseases including Parkinson's disease, Amyotrophic Lateral Sclerosis, Alzheimer's...

20060073123 - Adenovirus vectors for immunotherapy: The present invention provides compositions, methods and kits comprising viral vectors that may be used for performing immunotherapy. In particular, the present invention provides viral vectors having subgroup B adenoviral capsid fibers that are configured to express a transgene sequence in antigen presenting cells (e.g. dendritic cells) with a high...

20060073126 - Cytotoxic t lymphocyte: The present invention relates to a T lymphocyte having an activity to induce a T lymphocyte recognizing an antigen and a technique to use the T lymphocyte....

20060073124 - Identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue: Methods for the identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue. Specifically, this invention relates to an adult multipotent cell or a cell population or composition comprising said cell, isolated from non-osteochondral mesenchymal tissue, characterized in that the cell is positive for the following markers: CD9, CD10, CD13,...

20060073125 - Isolation and use of solid tumor stem cells: A small percentage of cells within an established tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give...

20060073128 - Means and methods for the modulation of arteriogenesis: The present invention relates generally to the modulation of arteriogenesis and/or the growth of collateral arteries or other arteries from preexisting arteriolar connections. In particular, the present invention provides a method for enhancing arteriogenesis and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections comprising contacting an...

20060073127 - Therapeutic alteration of transplantable tissues through in situ or ex vivo exposure to rna interference molecules: The present invention, at least in part, relates to the discovery of efficacious delivery of an RNAi agent (in preferred aspects of the invention, an siRNA) to a transplantable tissue. Organ rejection, transplantation-mediated transmission of viral infection, and triggering of apoptosis in transplanted tissues can each be minimized by the...

20060073129 - Composition and method for inhibition of microorganisms: A composition and method for the inhibition of microorganisms....

20060073130 - Methods and compositions for the dietary management of autoimmune disorders: The present invention describes the use of lactic acid bacteria, particularly lactic acid producing members of the genus Bacillus, in treating digestive-related immune disorders by downregulating of cytokines and by inhibiting pathogenic or deleterious microorganisms in the gastrointestinal tract. Specific formulations of Bacillus coagulans for various immune disorders are elaborated....

20060073121 - Spray formulation for pungency enhancement in capsicum: A method of preparation of spray formulation useful for improvement of pungency levels of Capsicum at field level is disclosed. The said spray applied to the Capsicum plants provides an enhanced pungency levels with respect to the levels of Capsaicinoids and also the intermediates of the Capsaicinoids biosynthesis. Said spray...

20060073122 - Method for activating human antigen presenting cells, activated human antigen - presenting cells, and use thereof: The invention relates to a method for activating human-derived antigen-presenting cells by in vitro cultivation with at least one of the glycoside compounds represented by formula (A) or salts thereof [preferred example: (2S,3S,4R)-1-(α-D-galactopyranosyloxy)-2-hexacosanoylamino-3,4-octadecanediol], and to human antigen-presenting cells activated by the method. The invention also relates to a method for...

20060073131 - Coenzyme q compositions persisting in blood: The object of the present invention is to provide a composition maintaining a blood coenzyme Q concentration at a high level in blood for a prolonged period of time, in order to surely attain an effect of coenzyme Q, which can be expected to manifest a superior effect in maintaining...

20060073132 - Agents for wound healing: The present invention relates to pharmaceutical compositions containing fragments of alpha-1 proteinase inhibitor (API) or chimeric proteins of API and insulin-like growth factor for use in stimulating wound healing....

20060073138 - Gridlock nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods: The invention provides a novel gene, gridlock, and its encoded protein. gridlock plays a role in vascular development and modeling, and a mutation in gridlock has been associated with an aortic arch disease, coarctation. Thus, gridlock nucleic acid molecules and polypeptides can be used in methods of diagnosing, treating, and...

20060073134 - Human diabetes-mediating proteins: Provided are human secreted and non-secreted diabetes mediating proteins, including protective and deleterious diabetes-mediating proteins, as well as polynucleotides encoding same, drug screening methods for identifying a test compound capable of altering the expression of a diabetes-mediating proteins, and methods of preventing or ameliorating diabetes by administering a compound capable...

20060073136 - Humanised antibodies: CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise...

20060073137 - Humanised antibodies: CDR-grafted antibody heavy and light chain comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise...

20060073135 - Methods and compositions for modulating and detecting wisp activity: Methods and compositions for use in modulating the activity(s) of WISP-1 polypeptide are pronided. WISP-1 antagonists inlcude anti-WISP-1 antiboties, WISP-1 immunoadhesins and WISP-1 variants (and fusion proteins thereof) which inhibit or neutralize induction or secretion of IIAS2, IIA, CD4 or RIIAMM by native human WISP-1 polypeptide in at least one...

20060073133 - Sialoadhesin factor-3 antibodies: Monoclonal antibodies have been generated that bind to human sialoadhesion factor-3. These antibodies are useful as diagnostic and therapeutic reagents....

20060073139 - Vaccine composition for preventing meningococcal disease: The present invention relates to an anti-idiotype antibodies directed against the monoclonal antibody (HmenB3) to Neisseria meningitidis serogroup B and hybridomas producing the anti-idiotype antibodies. This invention is also directed to vaccine compositions comprising the anti-idiotypic antibodies in combination with pharmaccutically acceptable carriers. These vaccine compositions can be used to...

20060073142 - Anti-fc-gamma riib receptor antibody and uses therefor: The present application describes antibodies that selectively bind human FcyRIIB, with little or no binding to other human FcγRs, e.g., human FcγRIIA. The invention also provides isolated bispecific antibodies comprising an antibody that selectively binds FcγRIIB, and a second antibody that specifically binds an activating receptor. Various uses, including therapeutic...

20060073141 - Compositions and methods for treating inflammatory disorders: The invention relates to compositions and methods for treating inflammatory disorders. More specifically, the invention relates to antibody compositions and their use in the treatment of inflammatory disorders....

20060073140 - Monoclonal antibodies to activated erbb family members and methods of use thereof: Antibodies which bind to activated members of the erbB, TNF, and IgSF family of receptors and pharmaceutical compositions comprising the same are disclosed. Peptides and mimetics of erbB, TNF, and IgSF receptors and pharmaceutical compositions comprising the same are also described. Methods of using such antibodies, peptides, and mimetics in...

20060073143 - Treatment with anti-erbb2 antibodies and anti-hormonal compounds: The present application describes methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies, and anti-hormonal compounds, such as anti-estrogens....

20060073144 - Individualized anti-cancer antibodies: The present invention relates to a method for producing patient specific anti-cancer antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies customized for the individual patient that can be used...

20060073147 - Gamma-1 and gamma-3 anti-human cd23 monoclonal antibodies and use thereof as therapeutics: Methods for inhibiting production of IgE in a human subject with an IgE-mediated allergic disorder by administering anti-CD23 antibodies....

20060073145 - Methods and compositions for inhibiting cd14 mediated cell activation: This invention provides hybridoma cell lines producing monoclonal antibodies which inhibit CD14 mediated cell activation. Monoclonal antibodies produced by these cell lines also are provided. The antibodies are useful for the detection of the presence of cell surface and soluble CD14 in a sample. Chimeric and CDR grafted antibodies generated...

20060073146 - Uses of agonists and antagonists to modulate activity of tnf-related molecules: Methods of using one or more agonists or antagonists to modulate activity of the members of the TNF and TNFR families referred to as TALL-1, APRIL, TACI, and BCMA are provided. The methods include in vitro, in situ, and/or in vivo diagnosis and/or treatment of mammalian cells or pathological conditions...

20060073148 - Il-13 binding agents: Agents (e.g., antibodies and fragments thereof) that bind specifically to IL 13 and modulate the ability of IL-13 to interact with IL-13 receptors and signaling mediators are disclosed....

20060073149 - Rapid improvement of cognition in condition related to abeta: The present invention is a method for effecting rapid improvement in cognition in subjects suffering from conditions or diseases related to the Aβ peptide, including Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy, mild cognitive impairment, and the like. The method comprises administering anti-Aβ antibodies to the subject, especially antibodies having...

20060073153 - Individualized anti-cancer antibodies: The present invention relates to a method for producing patient specific anti-cancer antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies customized for the individual patient that can be used...

20060073151 - Inhibitors of extracellular hsp90: The present invention describes inhibitors of extracellular Hsp90. The inhibition of extracellular Hsp90 leads to a reduction of the invasiveness of the tumor cells. Furthermore, the invention relates to the use of molecules inhibiting extracellular Hsp90 function for the manufacture of a medicament for the treatment or prevention of invasion...

20060073150 - Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer: A novel gene 08P1D4 (also designated STEAP-1) and its encoded protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The...

20060073152 - Therapeutic agents with decreased toxicity: The present invention relates to therapeutic agents with reduced toxicity comprising a serum albumin binding peptide (SABP), a targeting agent and a cytotoxic agent. The present invention also relates to methods for reducing the toxicity of therapeutic agents and methods of treatment using the therapeutic agents with reduced toxicity....

20060073154 - Group a streptococci bind to mucin and human pharyngeal cells through a sialic acid-containing receptor: The present invention comprises methods of inhibiting the interaction between group A streptococci or M protein and mucin or mucin producing cells by interfering with binding of M protein to sialic acid moieties of mucin, as well as methods of identifying modulators (e.g., inhibitors) of the interaction and novel M-protein...

20060073155 - Methods and compositions for diseases associated with amyloidosis: The present invention generally relates to the detection, treatment or prevention of disease states. Specifically, the present invention relates to the detection, treatment or prevention of amyloidosis or amyloid-associated diseases. The present invention further comprises methods and compositions comprising therapeutic vaccines, antisera and molecular constructs, comprising expression vectors and fusion...

20060073157 - Attenuated live neospora vaccine: The present invention provides attenuated live cultures of the pathogenic protozoan parasite, Neospora, and live vaccines against neosporosis prepared therefrom which are useful in the prevention of clinical disease and abortion in mammals....

20060073156 - Fosfomycin and n-acetylcysteine for the treatment of biofilms caused by escheric ia coli and other pathogens of the urinary tract: Pharmaceutical compositions for the treatment of infections by pathogens of the urinary tract and, more particularly, compositions containing fosfomycin optionally associated with N-acetylcysteine....

20060073159 - Human anti-cancer immunotherapy: The present invention encompasses compositions and methods for activating, stimulating and isolating antigen-specific T cells. The present invention also relates to compositions of antigen-specific T cells and methods of their use in the treatment and prevention of cancer, infectious diseases, autoimmune diseases, immune disfunction related to aging, or any other...

20060073158 - Methods and compositions comprising supramolecular constructs: The present invention comprises novel compositions and methods for eliciting high immune responses, of great specifity yielding conformationally sensitive antibodies. These antibodies recognize specific epitopes on a wide variety of antigens including but not limited to, amyloid protein, prion protein, P170 glycoprotein. The novel compositions of the invention comprise supramolecular...

20060073160 - Cloning of chicken anemia virus dna: Recombinant genetic information (DNA or RNA), comprising a Chicken Anemia Virus (“CAV”)-specific nucleotide sequence and the use thereof for diagnostics, vaccination or protein production. Recombinant CAV protein and the use thereof for diagnostics, vaccination or production of CAV-specific antibodies. The use of CAV-specific antibodies thus obtained....

20060073161 - Nucleic acid and amino acid sequences relating to bacteroides fragilis for diagnostics and therapeutics: The invention provides isolated polypeptide and nucleic acid sequences derived from Bacteroides fragilis that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting...

20060073162 - Preparation and standardization of immunomodulatory peptide-linked glucans with verifiable oral absorbability from coriolus versicolor: This invention provides compositions and methods for stimulating the immune system. Such methods include administering an extract, purified peptide-linked glucan or active component thereof from Coriolus versicolor. The methods are particularly useful for prophylactic and therapeutic treatment of secondary immunodeficiency, wherein the immunodeficiency is the result of an infection, a...

20060073163 - Anti-sepsis conjugate vaccine: The present invention provides an immunogenic conjugate comprising biologically deacylated gram-negative bacterial moieties linked to D. discoideum proteinase 1, as well as novel subunits thereof, and methods of making and using the conjugates in vaccines to treat sepsis and other infectious complications....

20060073164 - Dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications: The present invention relates to the development of viral vectors expressing different immunogens from the West Nile Encephalitis Virus (WNV) or the Dengue virus which are able to induce protective humoral and cellular immune responses against WNV or Dengue virus infections. More specifically, the present invention relates to three (3)...

20060073166 - Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders: The present invention pertains to methods for preventing reovirus recognition in the treatment of cellular proliferative disorders, and particularly ras-mediated cellular proliferative disorders, in mammals. The mammal may be selected from dogs, cats, sheep, goats, cattle, horses, pigs, mice, humans and non-human primates. The method comprises suppressing or otherwise inhibiting...

20060073165 - Vaccine against infectious agents having an intracellular phase, composition for the treatment and prevention of hiv infections, antibodies and method of diagnosis: A vaccine for treating and/or preventing infectious diseases where the infectious agent has at least one intracellular phase in the host during its multiplication cycle is disclosed. The vaccine comprises at least one cryptic epitope of a cellular element that is carried along by an intracellular infectious agent as it...

20060073167 - Vaccine for fish cold-water disease: The present invention provides a vaccine for the bacterial cold-water disease in fish comprising inactivated cells of Flavobacterium psychrophilium in the logarithmic growth phase or components thereo...

20060073168 - Neisseria meningitidis serogroup a capsular polysaccharide acetyltransferase, methods and compositions: Provided are recombinant DNA molecules that do not occur in nature encoding an O-acetyltransferase, vectors that direct expression of an O-acetyltransferase, recombinant host cells which express an O-acetyltransferase, methods for recombinant production of an O-acetyltransferase, methods for acetylating capsular polysaccharides, especially those of a Serogroup A Neisseria meningitidis using a...

20060073169 - Acellular antibordetella vaccine: The invention relates to an immunogenic composition, characterized in that it comprises an adenyl cyclase-hemolysin (AC-Hly) protein, or an immunogenic portion of this AC-Hly, of a strain of Bordetella chosen from B. pertussis, B. parapertussis or B. bronchiseptica, and in that it comprises, in addition, a bacterial extract containing the...

20060073170 - Vaccine complex for preventing or treating leishmaniases: A therapeutic vaccine complex for preventing or treating leishmaniases and infections mediated by intracellular pathogenic micro-organism in mammals and in particular in humans, members of the dog, car and horse family. The invention is characterized in that it includes excretion secretion molecules derived from Leishmania sp. Promastigotes produced in a...

20060073171 - Vaccine composition against malaria: A vaccine composition useful in the prevention or treatment of malaria comprises a plurality of malaria-derived antigens in combination with an adjuvant which is a preferential stimulator of TH1 cell response....

20060073174 - Adherent and erodible film to treat a moist surface of a body tissue: A thin, flexible, bilayer or multi-layer film which when applied to a moist surface of a body tissue adheres and delivers an active agent, pharmaceutical compound, nutraceutical, flavor or other substance to the underlying surface and/or body cavity and erodes at a predetermined rate. In one application, the amount of...

20060073173 - Large-scale manufacturing process for the production of pharmaceutical compositions: Methods for manufacturing pharmaceutical compositions with a predetermined surface tension or other properties are provided. Also provided are pharmaceutical compositions with a predetermined surface tension or other properties, articles of manufacture containing the pharmaceutical compositions and systems for preparation of the compositions....

20060073175 - Methods and formulations for delivery of pharmacologically active agents: In accordance with the present invention, novel formulations have been developed which are much more effective for the delivery of hydrophobic drugs to patients in need thereof than are prior art formulations. Invention formulations are capable of delivering more drug in shorter periods of time, with reduced side effects caused...

20060073172 - Stabilized ophthalmic solution for the treatment of glaucoma and lowering intraocular pressure: The present invention provides stable ophthalmic solutions comprising a compound with serotonergic 5-HT2 receptor activity and at least one stabilizer, together with methods of using such solutions to treat glaucoma and to lower intraocular pressure....

20060073177 - Gel composition: (B) at least one oily base, can be obtained in the form of a translucent to milky white, creamy to solid gel, with an attractive appearance. When employed in aromatic cosmetic compositions such as cosmetics, such gel compositions yield an aromatic cosmetic product that does not produce a clammy or...

20060073178 - Method and composition for restoration of age related tissue loss in the face or selected areas of the body: A treatment method for restoring of age related tissue loss in the face or selected areas of the body is disclosed which includes injecting an injectable composition containing a growth factor and hyaluronic acid as a carrier into the dermis, the hypodermis, or both, in various areas of the face,...

20060073176 - Water-soluble composition containing coenzyme q10: A water-soluble composition comprising (A) coenzyme Q10 of 5-40% by weight, (B) monoester of polyglycerol with average polymerization degree of 10 and fatty acid with 18 carbon atoms of 5-30% by weight, (C) mono-, di-, tri- or penta-ester of polyglycerol with average polymerization degree of 3-6 and fatty acid with...

20060073179 - Composite rodenticide: A non-toxic rodenticide comprises water-rodenticidal material such as alphacellulose (10) encapsulated within an enteric coating (11) of gastroresistant material such as glassy amylase or an acrylic polymer. The enteric coating can be pH-sensitive redox-sensitive or sensitive or enzymes in the gastrointestinal system of a rodent so as to release the...

20060073180 - One step fire ant control: The present invention relates to a method for controlling fire ants with a single step application of a combination of a bait and a controlled release treatment composition, and to the novel bait/controlled release treatment composition combination used in the method of the present invention....

20060073181 - Medical material made of titianium fiber: It is intended to provide a scaffold whereby a bone and a metallic material can three dimensionally form together a stereoscopic binding layer. Thus, a geometric space sufficient for cell actions is provided. As a result, the time required for the formation of a stereoscopic bond can be shortened and,...

20060073182 - Conveniently implantable sustained release drug compositions: This invention provides for biocompatible and biodegradable syringeable liquid, implantable solid, and injectable gel pharmaceutical formulations useful for the treatment of systemic and local disease states....

20060073183 - Therapeutic composition and a method of coating implantable medical devices: A therapeutic composition is provided including a polysaccharide or a cationic peptide dissolved in an organic substance. The polysaccharide can be heparin or a derivative of heparin. The cationic peptide can be L-arginine, oligo-L-arginine or poly-L-arginine. The organic substance can be formamide. A method of coating an implantable medical device...

20060073185 - Method and composition for contact lenses: A solution for soft, hydrogel contact lenses includes a polyether that is controllably released into an eye's tear film when the lens is worn. Polyether components of the subject solution are released from the soft contact lens material matrix over long time periods to produce longer lasting wetting performance, improved...

20060073184 - Viscoelastic composition, methods of use and packaging device with anti-oxidant: The present invention is directed to a viscoelastic composition comprising an aqueous solution having a viscoelastic polymer based upon the total volume of the viscoelastic composition. Typically, the viscoelastic composition further contains soluble vitamin derivative. The present invention also includes methods of use of the new viscoelastic composition and a...

20060073188 - Fast-dissolving isotropic expanded microporous composition or structure for pharmaceutical, veterinary, dietetic, food or cosmetic use and method for obtaining same: The invention relates to novel fast-disintegrating, or even instant-disintegrating, homogeneous microporous compositions for pharmaceutical, veterinary, food, dietetic or cosmetic use, intended for the oral route or to be applied in contact with the mucous membranes and a method for producing them....

20060073186 - Nutritional compositions: The present inventors discovered that the onset of galactosamine hepatopathy is suppressed by nutritional compositions comprising as essential ingredients: whey protein hydrolysates; lecithin and oils and fats high in oleic acid, which are able to improve the lipid metabolism; and palatinose having an insulin-sparing effect. Furthermore, the whey protein hydrolysate...

20060073187 - Use of arachidonic acid for normalization of infradian rhythm: A composition having a normalizing action for infradian rhythm and/or a synchronization promoting action for circadian rhythm (biological clock) containing arachidonic acid and/or an arachidonic acid-containing compound....

20060073189 - Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements: The present invention relates to gums, lozenges, candies, tablets, liquids and spray compositions that contain orally administered medications and dietary supplements that are released in the oral cavity. The medications and dietary supplements contained therein may be delivered in a multi-phase mode. The compositions may also contain buffer systems that...

20060073190 - Sealed, edible film strip packets and methods of making and using them: The invention provides, in one aspect, a method of making a confectionery packet or sachet formed with an edible film and enclosing a center composition. The packet or sachet can be designed to be placed in the mouth, where the film dissolves and the center composition is released. In preferred...

20060073191 - B-1, 4-mannobiose-containing composition: The present invention is to provide a β-1,4-mannobiose-containing composition which can inhibit colonization of salmonella in animal body and effectively excrete salmonella outside the body and the method for producing thereof, a feed additive containing the β-1,4-mannobiose-containing composition, and a feed blended with the β-1,4-mannobiose-containing composition. The present invention is...

20060073192 - Composition and method for use in cartilage affecting conditions: A method for decreasing cartilage abnormalities and preventing cartilage degradation in an animal using a combination at least one sulfur containing amino acid and manganese....

20060073193 - Enzyme granules: The present application relates to a steam treated pelletized feed composition comprising a granule comprising a core and a coating wherein the core comprises an active compound and the coating comprises a salt....

20060073194 - Methods and compositions for maintaining or enhancing feeding characteristics in post-receiving stressed animals: The present invention relates to methods and compositions for maintaining or enhancing feeding characteristics of post-receiving stressed animals using a saponin composition. In an embodiment, the invention includes a method for increasing feed intake of an animal after a post-receiving stressful event comprising administering an effective amount of a composition...

20060073195 - Tissue including a volatile rhinological composition: Tissues useful in providing fibrous tissue products for skin contact, such as facial tissue, bathroom tissue, disposable handkerchiefs which comprise a volatile rhinological effective composition for delivery to human skin....

20060073197 - Encapsulated transfer factor compositions and methods of use: Compositions comprising transfer factor and/or glucan, such as hybrid glucan, coated with a hydrophobic or lipid coating. The composition can be combined with nutraceuticals including zinc, essential fatty acids, lactic acid generating bacteria, etc. Also provided are methods for prevention and treatment of animal pathologies using these compositions as well...

20060073199 - Surfactant systems for delivery of organic compounds: Submicron particles of an organic compound, such as therapeutic and diagnostic agent are disclosed. The organic compound particles are associated with at least two surfactants including a block copolymer and phospholipids conjugated with a hydrophilic polymer....

20060073198 - Sustained release of antifectives: Provided are lipid antiinfective formulations substantially free of anionic lipids with a lipid to antiinfective ratio is about 1:1 to about 4:1, and a mean average diameter of less than about 1 μm. Also provided is a method of preparing a lipid antiinfective formulation comprising an infusion process. Also provided...

20060073196 - Use of p-glycoprotein inhibitor surfactants at the surface of a colloidal carrier: Use of a colloidal carrier for the manufacture of a medicament for inhibiting P-glycoprotein, wherein said colloidal carrier:—encapsulates or adsorbs a pharmacologically active substance, and—comprises P-glycoprotein inhibitor surfactants bound to the colloidal carrier surface....

20060073200 - Lercanidipine capsules: The invention provides a modified release lercanidipine pharmaceutical composition comprising at least one waxy substance and a therapeutically effective amount of lercanidipine, wherein oral administration of the modified release lercanidipine pharmaceutical composition to a patient results in a mean lercanidipine plasma concentration of greater than 0.5 ng/ml for the full...

20060073201 - Extended release formulation: This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of...

20060073202 - Dual component medicament delivery system: A medicament delivery system is disclosed. The system comprises a descending formulation for delivering the medicament and an ascending formulation to protect a patient being treated with the medicament from the side effects thereof....

20060073203 - Dry polymer and lipid composition: The present invention provides an orally administrable composition comprising a dry mixture of polymer, lipid and bioactive agent, being capable on contact with water or GI tract liquid of forming particles comprising said lipid and said bioactive agent and optionally also water. It is preferable that such particles have a...

20060073206 - Coating meltable substances and substance mixtures: The invention relates to a method for coating meltable substances or substance mixtures. A melt of the substance (mixture) drips into a melt of the coating agent(s) where it solidifies at least on the surface thereof and the solidified melt, which is coated on at least the surface thereof, is...

20060073205 - Controlled release granules comprising porous silica core: The present invention relates to controlled release granules for medical use comprising a drug loaded porous silica particle, and at least one layer of a controlled release coating material, characterized in that the drug loaded porous silica core is prepared by immersing dry porous silica particles with a solution, suspension...

20060073204 - Modified release oral pharmaceutical composition: The present invention relates to a modified release oral pharmaceutical composition comprising a core containing an active ingredient; and a coating surrounding said core, wherein said coating comprises a dispersion of water insoluble hydrophilic and hydrophobic polymers in a pharmaceutically acceptable organic solvent, which prevents the release of the active...

20060073207 - Protein biomaterials and biocoacervates and methods of making and using thereof: The present invention relates to protein biocoacervates and biomaterials and the methods of making and using protein biocoacervates and biomaterials. More specifically the present invention relates to protein biocoacervates and biomaterials that may be utilized for various medical applications including, but not limited to, drug delivery devices for the controlled...

20060073208 - Cosmetic neurotoxin compositions and methods: Cosmetic compositions include a Clostridial neurotoxin component and a microsphere component. In certain compositions, the composition includes a botulinum toxin and a plurality of swellable microspheres. The compositions are administered to individuals, by injection and the like, to treat a cosmetic defect of deficiency....

20060073210 - Nanoparticles for paracellular drug delivery: The invention discloses the nanoparticles composed of chitosan/poly-γ-glutamic acid characterized with a positive surface charge and their enhanced permeability through Caco-2 cells for paracellular drug delivery....

20060073209 - Nanoparticles for targeting hepatoma cells: The invention discloses the nanoparticles composed of γ-PGA-PLA block copolymers conjugated with galactosamine as a potential drug delivery system for treating liver cancers....

20060073211 - Cellulite formulation containing whole egg: A skin care formulation is provided, the formulation comprises whole egg, at least one herbal extract, at least one humectant and at least one aromatherapeutical substance or essential oil, whereby the formulation is used to reduce the visible appearance of cellulite. The formulation contains no caffeine, no aminophylline and no...

20060073212 - Method of treating respiratory disorders and airway inflammation: Compositions and methods for treating or preventing respiratory disorders and airway inflammation in an animal are disclosed. In one embodiment, the respiratory disorder is asthma. In one embodiment, the airway inflammation is asthma-related. In one embodiment, the respiratory disorder is cystic fibrosis. The method comprises administering an electrolyzed saline solution...

20060073213 - Reducing er stress in the treatment of obesity and diabetes: Endoplasmic reticulum stress has been found to be associated with obesity. Therefore, agents that reduce or prevent ER stress may be used to treat diseases associated with obesity including peripheral insulin resistance, hypergylcemia, and type 2 diabetes. Two compounds which have been shown to reduce ER stress and to reduce...

20060073214 - Colon cleansing composition and method: A composition and method for cleansing a colon prior to endoscopic procedure. More particularly, a combination of bisacodyl, metoclopramide, sodium, and/or a phosphorus containing composition administered in sequential doses for preparing a colon prior to colonoscopy....

20060073215 - Cough depressant composition containing iron for angiotensin-converting enzyme inhibitor inducing cough: The present invention relates to a cough depressant composition containing iron for angiotensin-converting enzyme inhibitor inducing cough. The cough depressant composition of the present invention comprises 0.01-100% by weight of Fe2+ (ferrous) or Fe3+ (ferric). Furthermore, the cough depressant composition of the present invention can comprise an angiotensin-converting enzyme inhibitor....

20060073216 - Compositions and methods for control of bovine mastitis: Bovine mastitis is prevented or controlled by treating at least teats of the animal with an effective antimicrobial amount of A) an aqueous microbiocidal solution of one or more active halogen species, which solution is a derivative product in an aqueous medium of (i) bromine, chlorine, and bromine chloride, or...

20060073217 - Methods of preventing weight gain: Methods for preventing or reducing weight gain due to factors such as drug use, cessation of smoking, and the like in a human subject, utilizing H1-receptor agonists that have a pharmacological half-life that allows an efficient treatment regime thereof are disclosed....

20060073218 - Antifungal composition, its fungicidal effect on pathogenic dermatophytes, and process for inhibiting growth of fungi: A natural preservative composition obtained from plant materials provides antimicrobial activity for use as an antifungal agent. The antifungal agent is effective in inhibiting the growth of Epidermophyton floccosum, Trichophyton mentagrophytes and Microsporum canis. The antimicrobial agent has a MIC as low as 0.03 μl/ml capable of inhibiting and/or killing...

20060073220 - Cinnamon extract enriched for polyphenols and methods of preparing same: The present invention provides extracts enriched in total phenols and methods of producing the same. In one embodiment, the extract is prepared from a woody biomass such as cinnamon. The enriched extracts can be prepared by a novel column purification step using a polymer resin that releasably adsorbs the phenolic...

20060073219 - Penetrating carrier, anti-fungal composition using the same and method for treatment of dermatophytes: A liquid carrier for topical administration is provided that contains a mineral oil, turpentine and, optionally, camphor, and optionally other terpenoid components containing pinene, and its use to provide an antifingal composition a mixture of antifungal essential oils and the carrier system, wherein the mixture of antifungal essential oils includes...

20060073221 - Compositions for the treatment of acquired immunodeficiency disease: This invention relates to compositions for the treatment of acquired immunodeficiency diseases, especially human immunodeficiency virus (HIV), and its simian and feline counterparts (simian immunodeficiency virus (SIV), and feline immunodeficiency virus (FIV)), and to methods for their use....

20060073222 - Triterpene compositions and methods for use thereof: The invention provides novel saponin mixtures and compounds which are isolated from the species Acacia victoriae and methods for their use. These compounds may contain a triterpene moiety, such as acacic or oleanolic acid, to which oligosaccharides and monoterpenoid moieties are attached. The mixtures and compounds have properties related to...

20060073223 - Phloridzin-rich phenolic fraction and use thereof as a cosmetic, dietary or nutraceutical agent: A phenolic fraction of fruit obtained from the Rosaceae family and also to the process for the specific extraction of this fraction. The phenolic fraction is rich in dihydrochalcones (phloridzin and phloretin) and may be used as a cosmetic, dietary, or nutraceutical preparation....

20060073224 - Method of preparing dioscorea tincture and uses thereof: The present invention is directed to method of making a wild yam root tincture from Diascorea sp. and a composition containing this tincture. The composition can be administered to an individual to treat conditions that are treatable with diosgenin....

20060073225 - Composition containing an extract of pericarpium zanthoxyli for protecting brain cells and improving memory: The present invention relates to a composition containing an extract of pericapium zanthoxyli for protecting brain cells and improving memory, and the composition of this invention induces an effect of protecting brain cells for modem people under brain damage that is caused by environmental factors, such as various stresses, drinking...